

REVIEW

Open Access

Bone-organ axes: bidirectional crosstalk

An-Fu Deng^{1,2}, Fu-Xiao Wang^{1,2}, Si-Cheng Wang^{1,2,3}, Ying-Ze Zhang^{4*}, Long Bai^{1,2,5,6*} and Jia-Can Su^{1,2,7*}

Abstract

In addition to its recognized role in providing structural support, bone plays a crucial role in maintaining the functionality and balance of various organs by secreting specific cytokines (also known as osteokines). This reciprocal influence extends to these organs modulating bone homeostasis and development, although this aspect has yet to be systematically reviewed. This review aims to elucidate this bidirectional crosstalk, with a particular focus on the role of osteokines. Additionally, it presents a unique compilation of evidence highlighting the critical function of extracellular vesicles (EVs) within bone-organ axes for the first time. Moreover, it explores the implications of this crosstalk for designing and implementing bone-on-chips and assembloids, underscoring the importance of comprehending these interactions for advancing physiologically relevant *in vitro* models. Consequently, this review establishes a robust theoretical foundation for preventing, diagnosing, and treating diseases related to the bone-organ axis from the perspective of cytokines, EVs, hormones, and metabolites.

Key words Bone-organ axes, Bidirectional crosstalk, Cytokines, Osteokines, Extracellular vesicles (EVs), Hormones, Metabolites

Background

The intricate network of crosstalk between organs is a fundamental aspect of physiological homeostasis and disease adaptation. Within the human body, bone serves not only as a structural support but also as an active participant in endocrine regulation through the secretion of bone-derived cytokines, known as “osteokines”[1]. Although the influence of bone on other organs has been extensively studied and reviewed[2], there has been a significant oversight regarding the reciprocal influence of these organs on bone physiology. As a result, there is currently a lack of comprehensive summarization and systematic analysis in this area. This bidirectional communication is referred to as the bone-organ axis. For example, in the brain-bone axis, while the brain exerts dominant effects on bone metabolism, homeostasis, and disease progression; conversely, bones also signal to the brain to promote brain development and skeletal growth. Understanding this bidirectional communication is crucial for comprehending the pathophysiology of bone diseases and systemic disorders.

The bidirectional crosstalk between bone and other

organs primarily occurs through the secretion of osteokines, hormones, and metabolites. For instance, osteocalcin (OCN), an osteokine synthesized by osteoblasts, plays a pivotal role in the maturation and functioning of reproductive organs[3,4]. Conversely, reproductive hormones such as testosterone and estrogen influence the bone remodeling and integrity[5].

Extracellular vesicles (EVs), a distinct category of lipid bilayer-bound particles naturally released by almost all cell types, have recently garnered considerable attention as potent mediators in intercellular communication[6]. In the growing field of research on their multifaceted capabilities, EVs have been implicated in diverse processes, ranging from immune modulation to tissue regeneration and even tumor progression[7-9]. Notably, recent finding has shed light on the profound impact of EVs on bone-organ crosstalk[10]. EVs secreted by bone-related cells have been shown to regulate the metabolic activities of distant organs, including the liver[11,12], adipose tissue[13], and muscle[14]. Reciprocally, brain-derived EVs containing microRNA (miR)-483-5p[15] and adipose tissue-derived EVs carrying miR-181a and miR-181b[16] influence bone homeostasis, highlighting their crucial significance in bone-organ crosstalk. Fundamentally, osteokines and EVs significantly orchestrate the bidirectional crosstalk within bone-organ axes, paving the way for novel insights into systemic physiology and disease.

This review aims to comprehensively elucidate the bidirectional crosstalk between bone and other organs (Fig. 1),

*Correspondence: yzhang@hebm.edu.cn; bailong@shu.edu.cn; jiacansu@shu.edu.cn

¹Institute of Translational Medicine, Organoid Research Center, Shanghai University, Shanghai 200444, China

⁴Department of Orthopaedics, the Third Hospital of Hebei Medical University, Orthopaedic Research Institution of Hebei Province, NHC Key Laboratory of Intelligent Orthopaedic Equipment, Shijiazhuang 050051, China
Full list of author information is available at the end of the article




Fig. 1 Bone-organ axes: bidirectional crosstalk

thereby providing insights into the treatment of bone-related diseases and systemic disorders. Furthermore, it briefly discusses the significance of unraveling bone-organ axes in the context of organ-on-chip, organoid, and assembloids research. Understanding these intricate interactions is crucial for developing not only more sophisticated and physiologically relevant *in vitro* models but also potential therapeutic applications for addressing bone-related and systemic diseases.

Bone-organ axes

Brain-bone axis: neuroendocrine regulation and skeletal health

The concept of the brain-bone axis refers to a bidirectional communication network between the central nervous system (CNS) and skeletal system, elucidating the intricate physiological interplay that underpins bone homeostasis and neuroregulation. Emerging evidence suggests that this axis encompasses not only hormonal and neuronal pathways but also integrates complex molecular and cellular mechanisms, highlighting the pivotal role of the CNS in skeletal health and

disease[17-19]. Significant advancements in neuroscience and bone biology have shed light on the molecular foundations of this axis, revealing how central signals can influence processes involved in bone remodeling, such as osteoblastogenesis and osteoclastogenesis, thereby impacting bone density, structure, and overall health. The hypothalamus directly affects osteoblast activity and bone formation through the secretion of hormones like leptin, emphasizing a crucial connection between metabolic states and bone density. Moreover, the discovery of OCN as a hormone derived from bones has further demonstrated the bone's role as an endocrine organ capable of influencing brain function and systemic energy metabolism[20]. Exploring the brain-bone axis opens up new avenues for understanding the pathophysiology of conditions like osteoporosis, arthritis, and other metabolic bone diseases while presenting potential therapeutic targets that leverage the neuroskeletal interface.

Brain to bone: neurological influence on skeletal integrity

The brain plays a dominant role in regulating bone metabolism, maintaining homeostasis, and influencing

disease progression. Conversely, bone communicates with the brain to facilitate brain development and promote bone growth. This section describes the impact of the brain on bone through various neuropeptides [such as neuropeptide Y (NPY), cocaine amphetamine-regulated transcript (CART), proopiomelanocortin (POMC), and neuromedin U (NMU)], neurotransmitters [including 5-hydroxytryptamine (5-HT, serotonin), dopamine (DA), and excitatory neurotransmitter glutamate (Glu)], cannabinoids (CBs), semaphorins (Semas), as well as EVs produced by the brain (Fig. 2a; Table 1 [21-71]).

NPY, a neuropeptide that regulates bone homeostasis, is expressed in the central and peripheral nervous systems to modulate the activity of osteoblasts and osteoclasts. Orexigenic NPY interacts with 5 distinct receptors [Y1 (NPY1R), Y2 (NPY2R), Y4 (NPY4R), Y5 (NPY5R), and Y6 (NPY6R)] to regulate multiple physiological functions. It exerts its influence on bone formation by suppressing osteoblast activity and promoting osteoclastogenesis through its Y1 and Y2 receptors. A study conducted in mice has reported that NPY binding to the osteoblast Y1 receptor enhances proliferation of mesenchymal stem cells (MSCs) and osteoprogenitor proliferation while inhibiting bone formation[21]. In a NPY2R-deficient mouse model, there was observed a bias towards increased bone formation, indicating an important role for this receptor in maintaining bone homeostasis[22].

Predominantly recognized for its influence on neuroendocrine functions related to appetite suppression and energy homeostasis, CART consists of two peptides (CART I and CART II) and extends its physiological impact on skeletal health by promoting osteoblast differentiation and proliferation[23]. The mechanisms through which CART exerts its osteogenic effects involve the modulation of crucial signaling pathways, including Wnt and bone morphogenetic proteins (BMPs), which are vital for osteoblast function and bone homeostasis. Given its dual role in energy regulation and bone metabolism, CART emerges as a potential therapeutic target for addressing bone diseases such as osteoporosis, offering a novel approach to enhancing bone density and strength through the manipulation of neuroendocrine pathways[23,24].

5-HT is biosynthesized in neurons within the CNS and has also been detected in the skeletal system[25]. It can bind to receptors on osteoblasts and osteoclasts, thereby influencing bone homeostasis[26]. Different sources of 5-HT have varying effects on bone metabolism[27]. Peripheral nerve-derived 5-HT inhibits bone formation, while central nerve-derived 5-HT promotes it[27]. Clinical evidence supports these findings, demonstrating accelerated bone loss and

reduced bone mass gain in postmenopausal women prescribed selective serotonin reuptake inhibitors[28]. Similarly, Semas are a family of cell surface and soluble proteins that include 3A (SEMA3A) and 4D (SEMA4D). They transduce cell signals and regulate cell differentiation and function[29]. Semas and their receptors are expressed both within the nervous system as well as outside it. SEMA3A exerts a dual regulatory effect on osteoblasts and osteoclasts by promoting osteoblast activity while inhibiting osteoclast activity[30]. Moreover, SEMA4D suppresses osteoblast formation and mineralization while inducing osteoclast formation during bone resorption[31].

In addition to the aforementioned factors, we briefly explore other key elements contributing to the complex brain-bone axis. POMC, a precursor protein, generates multiple peptides including adrenocorticotropic hormone (ACTH) and melanocyte-stimulating hormones, which possess immunomodulatory functions as well as protective effects on bone and cartilage[32,33]. Specifically, the absence of estrogen receptors in POMC-expressing neurons has been shown to increase cortical bone mass in female mice, highlighting the negative impact of estrogen on bone through POMC-expressing neurons[34]. NMU is a neuropeptide with widespread expression, particularly in the gastrointestinal tract and CNS, implicating its multifunctionality across various physiological domains such as energy homeostasis regulation and stress responses[35]. NMU primarily stimulates osteoblast proliferation and differentiation to promote bone formation. This effect is mediated by binding to specific receptors (NMUR1 and NMUR2), expressed on osteoblasts, triggering intracellular signaling cascades that enhance bone matrix production and mineralization[36]. Neurotransmitters also play a crucial role. For example, DA inhibits osteoclast generation through its receptors DRD1-DRD3[37,38] and DRD5[39], positively influencing bone mass[40]. This is particularly relevant considering the decreased levels of DA observed in conditions such as Alzheimer's disease, Parkinson's disease, and depression, which could have secondary implications for bone health. Glu, another neurotransmitter, is involved in maintaining bone homeostasis by binding to its ionotropic receptors on both osteoblasts[41] and osteoclasts[42,43]. Activation of these receptors inhibits osteoclast activity[44] while promoting osteoblast function[45], offering a balanced regulatory mechanism. CBs introduce an additional layer of intricacy, as they primarily bind to 2 receptor subtypes: CBR1 and CBR2. While CBR1 is mainly expressed in the CNS and stimulates bone resorption[46], CBR2 is primarily found in the peripheral nervous system and promotes bone formation by inhibiting




Fig. 2 Interconnected networks of the bone-organ axes.

This figure illustrates the complex network of communication pathways between the skeletal system and major organs, encompassing both physiological and pathological states. **a.** Within the bone-brain axis, a diverse array of molecules such as neuropeptides, neurotransmitters, and EVs orchestrate the communication between the brain and bone, underpinning cognitive functions and skeletal health; **b.** The lung-bone axis unravels how pulmonary processes and bone remodeling influence each other via osteokines, inflammatory markers, and EVs, with implications for conditions ranging from cystic fibrosis (CF) to chronic obstructive pulmonary disease (COPD); **c.** The liver-bone axis sheds light on the reciprocal interactions through hepatokines, osteokines, and EVs, which are pivotal in maintaining metabolic balance and responding to liver disease; **d.** The heart-bone axis reveals the bidirectional communication, where cardiac markers and EVs reflect the interplay affecting cardiovascular health; **e.** The kidney-bone axis focuses on the regulatory role of the kidneys in mineral and bone homeostasis, particularly through the modulation of phosphate and calcium levels, and the systemic implications of chronic kidney disease (CKD) on bone architecture. Each axis portrays a specific organ-bone interaction spectrum, from molecular signals to disease, providing a comprehensive view of the bone's central role in systemic physiology and pathology. GnRH. Gonadotropin-releasing hormone; GHRH. Growth hormone-releasing hormone; TRH. Thyrotropin-releasing hormone; CRH. Corticotropin-releasing factor; NPY. Neuropeptide Y; CART. Cocaine amphetamine-regulated transcript; 5-HT. 5-hydroxytryptamine; SEMA4D. Semaphoring 4D; SEMA3A. Semaphoring 3A; POMC. Proopiomelanocortin; NMU. Neuromedin U; DA. Dopamine; Glu. Glutamate; CB. Cannabinoid; OCN. Osteocalcin; LCN2. Lipocalin 2; DKK-1. Dickkopf 1; SOST. Sclerostin; GH. Growth hormone; TSH. Thyroid stimulating hormone; FSH. Follicle-stimulating hormone; ACTH. Adrenocorticotropic hormone; IL-1/6/8. Interleukin-1/6/8; TNF-α. Tumor necrosis factor-α; BMP-9. Bone morphogenetic protein-9; IGF-1. Insulin-like growth factor 1; LCAT. Lecithin-cholesterol acyltransferase; RANKL. Receptor activator of nuclear factor kappa-B ligand; OPG. Osteoprotegerin; sRAGE. Soluble receptors for advanced glycation end products; PTH. Parathyroid hormone; FGF-21/23. Fibroblast growth factor-21/23; COVID-19. Chronic coronavirus disease 2019; EVs. Extracellular vesicles; CVD. Cardiovascular disease; CCR2. C-C motif chemokine receptor 2; CCNB1. Cyclin B1; CDK8. Cyclin-dependent kinase 8; CDC6. Cell division cycle 6; NF2. Neurofibromin 2; VEGFR. Vascular endothelial growth factor receptor

Table 1. Neuroendocrine and osteokines in the brain-bone axis associated with bone metabolism and neuroregulation

Factor	Source	Target cell	Effect	Function and application	References
Brain to bone					
Neuropeptide Y (NPY)	Central and peripheral nervous systems	Osteoblasts and osteoclasts	Inhibits osteoblast activity, stimulates osteoclastogenesis	Regulates bone mass and energy balance, contributing to the anabolic processes in bone formation	[21,22]
Cocaine amphetamine-regulated transcript (CART)	Brain	Osteoblasts	Promotes osteoblast differentiation and proliferation	Involved in bone formation and energy homeostasis	[23,24]
5-hydroxytryptamine (5-HT, serotonin)	Brain, gut	Osteoblasts, osteoclasts	Modulates osteoblast and osteoclast activity	Influences bone mass and remodeling, with effects depending on its site of production. 5-HT produced by peripheral nerves inhibits bone formation, while 5-HT produced by central nerves promotes bone formation	[25-28]
Semaphorins (Semas)	Brain	Brain	Influence nerve growth, regulate osteoclast and osteoblast differentiation	Semas links bone metabolism with neurological functions. SEMA3A has a dual regulatory effect on osteoblasts and osteoclasts since it can promote osteoblast activity and inhibit osteoclast activity. SEMA4D inhibits osteoblast formation and mineralization and induces osteoclast formation during bone resorption	[29-31]
Proopiomelanocortin (POMC)	Brain	Osteoblasts, cartilage	Enhances osteoblast proliferation	Plays a role in bone growth and regeneration	[32-34]
Neuromedin U (NMU)	Brain, gut	Osteoblasts	Stimulates osteoblast proliferation and differentiation	Facilitates bone formation and enhanced bone matrix production and mineralization	[35,36]
Dopamine (DA)	Brain	Osteoclasts	Inhibits osteoclast activity	Affect positively bone density and turnover	[37-40]
Glutamate (Glu)	Brain	Osteoblasts, osteoclasts	Inhibits osteoclast activity and promotes osteoblast function	Maintain bone homeostasis	[41-45]
Cannabinoids (CBs)	Brain	Osteoblasts, osteoclasts	Affects osteoblast and osteoclast activity, influences bone turnover	Modulates bone metabolism. Agonists and antagonists of CB1 and CB2 have great potential in clinical bone repair therapy	[46-49]
Growth hormone (GH)	Hypothalamus	Osteoblasts	Stimulates IGF-1 production; Promotes osteoblast differentiation and proliferation	Enhances bone growth and density by stimulating bone formation; Regulates longitudinal growth and bone mass	[50]
Follicle-stimulating hormone (FSH)	Hypothalamus	Ovaries, testes, osteoclasts	Increases estrogen and testosterone production; May enhance osteoclast differentiation	Indirectly influences bone density through regulation of sex steroids	[51-53]
Thyroid stimulating hormone (TSH)	Hypothalamus	Thyroid gland, osteoblasts, osteoclasts	Stimulates thyroid hormone (TH) production; Modulates osteoblast and osteoclast activity	Regulates bone turnover and density through THs; Hyperthyroidism can lead to increased bone resorption	[54-56]
Adrenocorticotropic hormone (ACTH)	Hypothalamus	Adrenal cortex, osteoblasts	Stimulates cortisol production; Influences osteoblast differentiation	High levels of ACTH can lead to decreased bone formation	[57-59]

(Continued)					
Factor	Source	Target cell	Effect	Function and application	References
Bone to brain					
Osteocalcin (OCN)	Bone	Pancreatic β cells, brain, gonads	Increases insulin secretion, affects cognitive functions, influences testosterone production	Links bone metabolism with glucose homeostasis, cognitive function, and fertility	[60,61]
Lipocalin 2 (LCN2)	Bone	Hypothalamus	Mediate the anorexia pathway to regulate energy metabolism binding to MC4R	Bone homeostasis is biased towards bone formation in MC4Rdeficient mouse model	[62-64]
Sclerostin (SOST)	Bone	Osteoblasts	Inhibits osteoblast activity and bone formation	Regulates bone remodeling and density, antagonist of Wnt signaling in bone formation	[65-68]
Dickkopf-1 (DKK1)	Bone	Osteoblasts	Inhibits osteoblast activity by antagonizing Wnt signaling	Controls bone remodeling and development, involved in the pathogenesis of neurodegenerative diseases to bone	[69-71]

IGF-1. Insulin-like growth factor-1; MC4R. Melanocortin 4 receptor

receptor activator of nuclear factor kappa-B (NF- κ B) ligand (RANKL)[47]. In clinical studies, activation of CBR1 has been shown to inhibit the release of norepinephrine, a transmitter of the sympathetic nervous system, thereby stimulating bone formation[48]. Conversely, deficiencies in the gene encoding CBR2 have been associated with low bone mineral density (BMD) and osteoporosis[49]. Therefore, agonists and antagonists targeting CB1 and CB2 receptors hold significant potential for clinical applications in bone repair therapy.

The pituitary gland is situated below the hypothalamus. Its particular anatomical location results in direct regulation of most hormones secreted by the pituitary gland in the brain (Fig. 2a; Table 1). Among them, we examine the impact of growth hormone (GH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and ACTH on bone metabolism.

Regulated by hypothalamic secretion of GH-releasing hormone (GHRH), GH is a bone regulatory factor produced by the anterior pituitary gland that exerts a positive influence on bone mass. Numerous studies have demonstrated that GH primarily acts through the release of insulin-like growth factor 1 (IGF-1)[72-74], which bind to glycoprotein-coupled receptors on osteoblasts, thereby promoting osteoblast proliferation[50,73]. FSH, a major regulator of sex hormone secretion, is regulated by the hypothalamic secretion of gonadotropin-releasing hormone (GnRH). FSH directly affects bone cells and plays a role in promoting bone mass. FSH receptors are present in osteoblasts, their precursors, and MSCs, but not in mature osteoblasts[51,52]. *In vitro* experiments have revealed that FSH binding to receptors on osteoblasts and their precursors stimulates osteoclast differentiation and function[53]. However, while the overall regulation of human bone mass by FSH has not been conclusively demonstrated *in vitro* experiments, some non-human studies suggest its negative impact on bone[51]. TSH, regulated by the hypothalamic secretion of thyrotropin-releasing hormone (TRH), affects bone metabolism through direct binding to TSH receptors expressed in osteoblasts and osteoclasts[54]. Additionally, TSH indirectly influences bone modeling *via* its effects on thyroid secretion. In osteoclasts, activation of TSH receptors inhibits signaling pathways involving Janus kinase (JNK) and NF- κ B inhibitor alpha (NFKBIA/I κ -B α), as well as the activities related to Jun proto-oncogene activator protein 1 (AP-1) transcription factor subunit (JUN/c-Jun) and NF- κ B, and the expression of genes such as *AP-1* and tumor necrosis factor- α (*TNF- α*)[55]. Activation of TSH receptors in osteoblasts downregulates their differentiation and proliferation through regulators

like Runt-related transcription factor 2 (RUNX2), osterix (OSX), and low-density lipoprotein receptor-related protein 5 (LRP5) [56]. Mice lacking TSH receptors in osteoblasts exhibit a phenotype characterized by low bone mass [54]. Similarly, regular administration of low-dose TSH injections to rats or mice increased bone mass [55]. ACTH, regulated directly by hypothalamic corticotropin-releasing factor (CRH), is released from the pituitary gland to stimulate glucocorticoid secretion from the adrenal gland. Glucocorticoids play a significant role in maintaining bone homeostasis [57]. Chronic elevation of glucocorticoid levels is a recognized cause of osteoporosis and reduced bone density [58]. Specifically, the binding of glucocorticoids to osteoblast receptors can directly inhibit osteoblast formation [59]. Additionally, glucocorticoids have been found to negatively impact growth plate cartilage proliferation [59].

Brain-derived EVs from patients with Alzheimer's disease have been investigated for their role in both bone and brain physiology. Liu *et al.* [15] found that brain-derived miR-483-5p can effectively traverse the blood-brain barrier (BBB) to affect bone homeostasis. Specifically, miR-483-5p originating from Alzheimer's disease brain was observed to induce a shift in the differentiation of bone marrow MSCs (BMSCs) from osteogenesis to adipogenesis, resulting in an imbalance between bone and fat tissue. In clinical settings, traumatic brain injury (TBI) has been shown to exacerbate bone healing processes [75]. However, the specific mechanism underlying this phenomenon is still under investigation. Xia *et al.* [76] demonstrated that hippocampal neurons release miR-328a-3p and miR-150-5p following TBI, which targeted osteoprogenitors to stimulate bone formation. They further injected a hydrogel enriched with miR-328a-3p into rat models with calvarial defects and observed a remarkable reparative effect. The brain-bone axis represents a dynamic system intricately regulated by many factors, each offering unique therapeutic targets for disorders related to bone. This axis serves as a nexus for potential interventions ranging from hormonal and neuropeptide pathways to neurotransmitter and CB signaling.

Bone to brain: bone-derived signals influencing neural function

A substantial body of experimental and clinical evidence demonstrates a reciprocal relationship between bone and the brain. Bone exerts its influence on the brain through various mediators derived from bone, including OCN, lipocalin 2 (LCN2), osteocyte-specific sclerostin (SOST), Dickkopf 1 (DKK1), and EVs (Fig. 2a; Table 1).

OCN, a mediator derived from bone, is induced by the bone gamma-carboxyglutamate protein expressed in osteoblasts

to participate in systemic regulation [60]. OCN is implicated in brain development and cognition and has been shown to traverse the BBB into the CNS, promoting spatial learning and memory while preventing anxiety behaviors [61]. During fetal development, maternal OCN traverses the placenta to facilitate infant nervous system development and inhibit apoptosis of hippocampal neurons [61]. Furthermore, OCN is associated with neurodegenerative diseases and holds potential as a hormone for their treatment [61].

Similarly, LCN2, another glycoprotein derived from bone, is capable of crossing the BBB and binding to the melanocortin 4 receptor (MC4R) in the hypothalamus. This interaction plays a crucial role in mediating the anorexia pathway and regulating energy metabolism [62,63]. In an MC4R-deficient mouse model, it was observed that there was a bias towards bone formation with increased bone mass in terms of maintaining bone homeostatic balance. Interestingly, despite correcting severe obesity which is typically associated with MC4R deficiency, the elevated levels of BMD were not restored [64].

Moreover, SOST, an osteocyte-specific glycoprotein, disrupts the Wnt/ β -catenin signaling by binding with LRP4/5/6, leading to the disturbance of bone metabolic homeostasis in favor of bone resorption [65,77]. Consequently, inhibiting SOST secretion has been proposed as a therapeutic approach for reduced bone density [66]. Romosozumab, a monoclonal antibody targeting SOST, has been developed and approved in the USA and Europe for the treatment of severe osteoporosis [78]. Within the brain, the Wnt/ β -catenin pathway plays a crucial role in processes such as neurotransmission, neuronal metabolism, synaptic plasticity, and BBB function. The involvement of the Wnt/ β -catenin pathway is also relevant to Alzheimer's disease pathophysiology [79]. However, it should be noted that SOST is expressed in other tissues as well [67]. Therefore, further studies are needed to confirm whether osteocyte-derived SOST can influence Wnt/ β -catenin signaling in the brain [68].

Furthermore, DKK1 functions as an antagonist of the Wnt signaling pathway. It exerts its antagonistic effects by binding to LRP6 in bone tissue, leading to a reduction in BMD when over-expressed [69,80]. More importantly, DKK1 plays a crucial role in cell death and differentiation during embryonic development, with its overexpression resulting in neuronal dysfunction and apoptosis [70]. Additionally, DKK1 expression is generally upregulated in the aging brain [81], while Wnt pathway signaling is frequently diminished [71]. DKK1 serves as a marker commonly found in neurodegenerative diseases such as Alzheimer's disease where it is upregulated among clinical patients [82].

The efficacy of BMSCs in the treatment of CNS diseases has been extensively researched and remains a topic of debate. Transplanted BMSCs has the potential to promote nerve repair by adopting functional neuronal and glial cell phenotypes[83-85]. However, it has been suggested that the primary mechanism through which BMSCs function is paracrine signaling rather than intracellular mechanisms[86]. EVs derived from BMSCs (BMSC-EVs) offer therapeutic potential due to their inherent stability, limited immunogenicity, and ability to cross the BBB or targeted delivery to the affected area[86]. These discoveries advance our understanding of BMSC-EVs and their contributions to brain protection and repair. By modulating microglial phenotypes from M1 to M2, BMSC-EVs alleviate cerebral infarction and mitigate short-term neurobehavioral impairments in rats[87].

The roles of non-coding RNAs within EVs have been investigated due to their capacity for transmitting information[88]. BMSC-EVs enriched with miR-124 were administered to mice in a transient middle cerebral artery occlusion (MCAO) model, resulting in reduced activation of proinflammatory microglial, preservation of BBB integrity, and mitigation of stroke-induced injury, potentially involving peroxiredoxin 1[89]. While miR-124-3p is downregulated in rats with hypoxic-ischemic brain damage (HIBD), treatment with BMSC-EVs can upregulate miR-124-3p levels, leading to improved neurologic function, inhibition of oxidative stress, and reduction in neuronal apoptosis[90]. BMSC-EVs enriched with miR-124 hold promising therapeutic potential for the treatment of clinical HIBD.

LCN2 demonstrates elevated expression and functions as a downstream target of miR-138-5p. In their study utilizing an MCAO mouse model to investigate the *in vivo* impact of miR-138-5p carried by BMSC-EVs in ischemic stroke, Deng et al.[91] demonstrated that miR-138-5p attenuated neurological impairment in ischemic stroke through targeted regulation of LCN2, thereby promoting astrocyte proliferation and suppressing inflammatory responses. Additionally, using a rat MCAO model, Dong et al.[92] found that BMSC-EVs ameliorated cerebral infarction *via* transfer of miR-23a-3p. Moreover, Singleton et al.[93] revealed that BMSC-EVs activated NF- κ B signaling and facilitated osteoclast differentiation from bone marrow cells in mice with TBI. These findings imply a potentially pivotal role for miR-1224 in inducing osteoclast differentiation during TBI-induced bone loss[93].

BMSC-EVs ameliorated HIBD in mice with MCAO by modulating the histone deacetylase 4 (HDAC4)/B-cell leukemia/lymphoma 2 (BCL2) axis and delivering miR-93

to prevent neuronal death in the hippocampus[94]. BMSC-EVs containing the long non-coding RNA ZNF1 antisense RNA 1 (ZFAS1) exhibited a potentially therapeutic effect on ischemic brain injury[95]. Shen et al.[96] demonstrated that BMSC-EVs transported miR-410 to target HDAC4, thereby preventing brain damage in hypoxic-ischemic mice. The protective effect may be attributed to the downregulation of phosphatase. Xiong et al.[97] reported that miR-129-5p derived from BMSC-EVs alleviated early brain injury in rats after subarachnoid hemorrhage by inhibiting the antiapoptotic and anti-inflammatory effects mediated *via* the high mobility group box 1 (HMGB1)/Toll-like receptor 4 (TLR4) pathway. Additionally, Cui et al.[98] reported elevated levels of miR-21 in the brains of Alzheimer's disease mice after treatment with EVs derived from hypoxia-preconditioned BMSCs. Moreover, supplementation with miR-21 reversed cognitive deficits and prevented degenerative features in APP/PS1 mice. Furthermore, Sha et al.[99] emphasized the critical role of the Wnt/ β -catenin pathway activation and the delivery of miR-29c-3p to hippocampal neurons *via* BMSC-EVs for reducing amyloid-beta deposition and inflammatory cytokines thus ameliorating cognitive function in rats with Alzheimer's disease.

In summary, the brain-bone axis is a dynamic system regulated by many signaling pathways. Factors influencing this axis can be categorized into neuropeptides (e.g., NPY and CART), neurotransmitters (e.g., 5-HT and DA), CBs, Semas, EVs, and pituitary hormones (e.g., GH and FSH). Neuropeptides such as NPY and CART directly impact osteoblast and osteoclast activity, thereby influencing bone formation and resorption. Neurotransmitters like 5-HT and DA exhibit varying effects on bone mass, often linked to their systemic levels in different diseases. CBs demonstrate a dual role in bone formation and resorption through their receptors. Semas including SEMA3A and SEMA4D regulate the activities of osteoblasts and osteoclasts, presenting potential therapeutic targets. Pituitary hormones regulated by the brain also significantly influence bone metabolism. Brain-derived EVs show promising roles in promoting both bone and brain health through specific microRNAs that affect bone homeostasis. In terms of clinical applications, these factors offer both advantages and challenges. Neuropeptides and neurotransmitters hold potential as therapeutic targets but require precise modulation due to their systemic effects. CB-based treatments offer promise but necessitate careful balancing to avoid adverse effects. Sema-targeted therapies could be effective but need further exploration for specificity. Pituitary hormone therapies have shown efficacy but require

individualized treatment plans due to complex hormonal interactions. Brain-derived EVs represent a novel area with promising potential for targeted therapy with minimal invasiveness; however, their clinical translation is still in the early stages.

Lung-bone axis

In the interplay between the lungs and bone, primary lung lesions such as lung tumors and chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), chronic coronavirus disease 2019 (COVID-19), and regional inflammation lesions, produce factors that exert effects on bone cells. Conversely, bone produces related factors that affect the lungs. Most studies on the cross-linking between the lungs and bone have primarily focused on lung diseases [100-104]. Their findings suggest that BMSC-EVs could represent a promising therapeutic strategy for acute lung injury (ALI) and other respiratory diseases. Therefore, this section aims to describe the interactions between the lungs and bone in relation to lung diseases (Fig. 2b).

In one study, it was observed that lung tumors stimulated the generation and recruitment of tumor-supportive BMSCs [100]. Specifically, these tumors activated osteoblasts residing in bone tissue which subsequently triggered the production of neutrophils. Engblom *et al.* [100] discovered that primary lung tumors in mice remotely activated osteoblasts expressing OCN⁺ by releasing soluble receptors for advanced glycation end products into circulation. The activation of osteoblasts resulted in generating a subset of neutrophils characterized by their elevated expression of sialic acid-binding Ig-like lectin F. Ultimately, it was found that these neutrophils returned to the site of the lung tumor, where they provided support for tumor growth.

COPD is recognized as a chronic inflammatory pulmonary disease accompanied by various intricate syndromes, including osteoporosis and diabetes, primarily induced by smoking. Osteoporosis-associated conditions can further exacerbate pulmonary function and symptoms in COPD patients, leading to a detrimental cycle. The mechanisms underlying osteoporosis in individuals with COPD remain unclear. During the initial stages of inflammation in COPD patients, exposure of lung epithelial cells to smoke particles results in the release of factors such as interleukin (IL)-1, TNF- α , and IL-8, contributing to the recruitment of immune cells. The post-inflammatory response also involves activation of T helper 1, 2, and 17 cells along with sustained activation of lung stem cells. Multiple factors produced during lung regional inflammation drive increased systemic inflammation and comorbidities (including osteoporosis), some of which are also considered

therapeutic targets for stage 3 COPD [101,105-107].

The most prevalent autosomal recessive genetic disorder, CF, is caused by mutations at a specific locus within the CF transmembrane conductance regulator gene [108]. Clinically, CF is accompanied by osteopenia and osteoporosis [109]. Patients with CF have been found to exhibit reduced levels of circulating OCN associated with vertebral fractures [110]. Conversely, lower serum OCN levels were correlated with higher ratio of RANKL/osteoprotegerin (OPG) in children aged 5–9 years with CF, indicating an imbalance favoring bone resorption in terms of bone homeostasis [102].

COVID-19 is a syndrome characterized by pneumonia and other complications resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [103]. Qiao *et al.* [111] used SARS-CoV-2-infected hamsters as a model for human infection to study bone metabolism during the acute pneumonia and recovery phases. They observed an upregulation of tartrate-resistant acid phosphatase (TRAP)+ osteoclast expression of nuclear factor of activated T cells 1 (Nfatc1), which was associated with a notable increase in bone resorption. More importantly, analysis of various bone tissues collected from hamsters revealed systemic rather than localized bone loss. Such bone loss in patients with COVID-19 may impede recovery, as low BMD is a risk factor for vertebral fractures and likely contributes to the deterioration of respiratory function during the rehabilitation phase. In addition, they also found that hamsters infected with SARS-CoV-2 exhibited an immune response in the respiratory tract, leading to the production of inflammatory cytokines (i.e., IL-1 β , TNF- α , and interferon γ). These cytokines were transported through the bloodstream to skeletal tissue where they promoted osteoclastogenesis.

The bone is a frequently affected site for the metastasis of lung cancer. Research findings have demonstrated that EVs in lung cancer possess the ability to influence bone physiology, as depicted in Fig. 2b. Taverna *et al.* [112] observed that EVs derived from non-small cell lung cancer (NSCLC) can activate the amphiregulin-induced epidermal growth factor receptor (EGFR) pathway, resulting in increased RANKL expression in bone cells. Consequently, RANKL stimulates the production of proteolytic enzymes indispensable for osteoclastogenesis, thereby initiating a detrimental cycle associated with osteolytic bone metastasis. Additionally, Xu *et al.* [113] demonstrated that exosomal miR-21 derived from the tumor tissues of patients with lung adenocarcinoma promotes osteoclast formation, making it a promising therapeutic target for managing bone metastasis.

Furthermore, studies have revealed that BMSC-EVs

provide novel insights into the treatment of bone diseases. Hua *et al.*[114] investigated the regulatory mechanisms and potential therapeutic applications of small BMSC-EVs containing miR-34c in targeting the epithelial sodium channel (ENaC) *via* myristoylated alanine-rich protein kinase C substrate (MARCKS). Their study using a mouse model demonstrated that miR-34c could enhance ENaC expression by binding with MARCKS and activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, thereby promoting alveolar fluid clearance and potentially alleviating lung edema. Liu *et al.*[115] explored the role of miR-let-7i encapsulated in BMSC-EVs in lung cancer progression. They discovered that miR-let-7i could suppress lung cancer through the lysine demethylase 3A (KDM3A)/doublecortin-like kinase 1 (DCLK1)/FXRD domain-containing ion transport regulator 3 (FXRD3) axis *in vivo* using nude mice, suggesting a potential therapeutic strategy for treating lung cancer. Additionally, Liu *et al.*[116] investigated how hypoxic BMSC-EVs promote lung cancer progression and elucidated the involvement of miR-328-3p and the neurofibromin 2 (NF2)-mediated Hippo axis in lung cancer development. They revealed that under hypoxic conditions, BMSC-EVs stimulated the expansion and dissemination of lung cancer cells through miR-328-3p- and NF2-mediated Hippo pathways *in vivo* using nude mice models. Wang *et al.*[117] proposed the potential role of microRNA transfer in mediating the effects of MSC-EVs on ALI. Their findings suggest that the transfer of lentivirus-transduced BMSCs carrying miR-27a-3p or knocking out miR-27a-3p *in vivo* can modulate macrophage polarization and alleviate ALI. Liang *et al.*[118] investigated the inhibitory effects of miR-144 derived from BMSC-EVs on NSCLC progression by targeting cyclins E1 and E2, which was further validated *in vivo* experiments.

In summary, the lung-bone axis entails an intricate interplay of cellular and molecular mechanisms. The emerging role of BMSC-EVs is particularly noteworthy, offering innovative therapeutic strategies for ALI and other respiratory conditions. Given the nascent state of current literature, numerous mechanistic details remain to be elucidated. For example, the precise involvement of cytokines such as IL-1 and TNF- α in COPD-induced osteoporosis remains unclear, necessitating further investigation. Similarly, the systemic bone loss observed in patients with COVID-19 raises new questions regarding long-term rehabilitation and treatment strategies. These gaps in our understanding not only offer avenues for future research but also represent potential targets for therapy. From a clinical perspective, these interactions present both opportunities and challenges. Understanding these bidirectional influences can

assist in developing targeted therapies for conditions such as lung cancer metastasis and ALI. However, the complexity of these interactions poses a challenge specifically when ensuring focused treatment without unintended systemic effects.

Liver-bone axis

The interaction between the liver and bone differs under normal physiological and pathological conditions (Fig. 2c). Patients with chronic liver disease often experience osteoporosis/osteopenia/fractures, particularly those with cirrhosis and cholestatic diseases. However, the mechanisms underlying osteoporosis in individuals with chronic liver disease are multifactorial, and the precise mechanisms remain unclear. Thioacetamide can induce liver damage in Sprague-Dawley rats, which serve as ideal animal models for studying abnormal bone metabolism after liver injury[119].

Extensive *in vitro* and *in vivo* evidence has shown that IL-6 is upregulated during liver injury and subsequently affects bone metabolism in various liver diseases[120,121]. Additionally, both animal model studies and clinical data indicate that ethanol appears to stimulate osteoclast activity by inducing IL-6 and TNF- α [122,123], which have similar effects on osteoporosis observed in viral hepatitis and nonalcoholic steatohepatitis. Moreover, vitamin D and 25-hydroxylation of vitamin D levels were found to be decreased in patients with nonalcoholic fatty liver disease[124] or alcoholic liver disease[125], characterized by impaired hepatic function and cholestasis. These reductions were associated with the presence of osteoporosis[126,127].

Fibroblast growth factor-21 (FGF-21) is a hepatic-produced factor that, when deficient, can impair liver cell function[128]. FGF-21 exerts a negative impact on bone mass[129]. Overexpression of FGF-21 in transgenic mice resulted in a significant decrease in BMD[130]. Bone morphogenetic protein-9 (BMP-9), a circulating factor produced by hepatic stellate cells, is expressed in the adult liver[131]. Zhou *et al.*[132] demonstrated that in ovariectomized mice, the overexpression of BMP-9 not only led to increased levels of BMP-9 in liver but also inhibited bone resorption activity, enhanced bone formation, and improved bone strength. Additionally, Guanabens *et al.*[133] suggested that SOST plays a pivotal role in regulating the Wnt/ β -catenin pathway in bone formation among patients with primary biliary cholangitis. SOST is produced by osteocytes and inhibits osteoblast proliferation and differentiation. It binds to LRP5/6 to counteract Wnt signaling and restricts bone formation[134,135]. Importantly, hepatocyte-secreted IGF-1 has an anabolic effect on bone growth by inhibiting osteoblast apoptosis and promoting osteoblastogenesis

through stabilization of the Wnt/ β -catenin pathway [136,137]. Furthermore, IGF-1 reduced bone resorption through the OPG and RANKL signaling pathways [138].

Hepatic osteodystrophy (HOD) is a chronic liver disease characterized by metabolic bone disease, often presenting with significant bone loss. Lu *et al.* [139] found that upregulating hepatic phosphatase protein phosphatase 2 catalytic subunit alpha (Ppp2ca/Pp2aca) during HOD resulted in the downregulation of the hepatokine lecithin-cholesterol acyltransferase (LCAT) activity. LCAT dysfunction further exacerbated bone loss in mice with HOD. The underlying mechanism involves LCAT's role in maintaining intracellular cholesterol dynamic homeostasis, which supports the activities of osteoblasts and osteoclasts. Interestingly, upregulation of LCAT expression in HOD model mice improved liver fibrosis and bone loss phenotypes.

Bidirectional communication mediated by EVs exists between liver cancer and bone (Fig. 2c). Wei *et al.* [140] transfected HepG2 cells (a hepatoma cell line) with miR-181d-5p mimics and inhibitors, followed by isolated EVs for coculture with BMSCs to evaluate their growth potential. Subsequently, the cocultured BMSCs were transplanted into nude mice to observe the progression of liver cancer cells. The study demonstrated that HepG2-EVs induced BMSC differentiation and exacerbated liver cancer metastasis through the delivery of miR-181d-5p both *in vitro* and *in vivo*. Han *et al.* [141] revealed that miR-3190-5p is transferred from EVs derived from bone-metastasized hepatocellular carcinoma to orthotopic tumor cells, thereby enhancing their metastatic capacity. This effect was achieved by downregulating AlkB homolog 5 RNA demethylase (ALKBH5) expression, which modulates gene expression through N⁶-methyladenosine-dependent and -independent manners.

BM-derived EVs have long been transplanted *via* orthotopic liver transplantation (OLT) in mice, which is a focal point of research due to its potential protective and reparative effects in liver diseases. Using an OLT mouse model, Zhou *et al.* [142] discovered that BMS-CEVs could induce M2 polarization of Kupffer cells and carry miR-22-3p, thereby improving liver function and reducing inflammatory cytokines. Haga *et al.* [143] explored the potential of BMSC-EVs in enhancing survival in a mouse model of lethal hepatic failure. Their results showed that deficiency of Y-RNA-1 attenuated the mitigating effects of BMSC-EVs on hepatocyte apoptosis induced by TNF- α /actinomycin D *in vitro*, suggesting a therapeutic role of Y-RNA-1 in repairing liver injury and highlighting the value of clinical studies [143]. Xuan *et al.* [144] revealed that enriching miR-148a-5p in BMSC-EVs could alleviate thioacetamide-

induced hepatic fibrosis in mice by targeting SMAD family member 4. Zhang *et al.* [145] used a mouse model of acute liver failure to explore the molecular mechanisms regulating hepatocyte proliferation and apoptosis in response to treatment with human BMSC-EVs. Specifically, they found that miR-20a-5p derived from BMSCs promoted hepatocyte proliferation and inhibited apoptosis through the phosphatase and tensin homolog (PTEN)/Akt pathway by downregulating PTEN expression and promoting Akt as well as glycogen synthase kinase-3 β phosphorylation.

The section delved into the intricate interplay between the liver and bone, distinguishing factors based on their roles in the liver-bone axis and evaluating their clinical implications. Factors influencing this crosstalk were classified as follows: 1) inflammatory mediators (e.g., IL-6 and TNF- α), which are upregulated during liver injury and impact bone metabolism; 2) metabolic regulators (e.g., vitamin D and FGF-21), with vitamin D deficiency associated with osteoporosis and FGF-21 negatively affecting bone mass; 3) regulators of bone formation and resorption (e.g., BMP-9, SOST, and IGF-1), where BMP-9 enhances bone formation, SOST restricts it, and IGF-1 promotes osteoblastogenesis; and 4) EVs, which play roles in interactions between liver cancer cells and bone, offering potential for therapeutic applications. The advantages for clinical application include potential therapeutic targets such as the Wnt/ β -catenin pathway and BMSC-EVs for liver repair. However, limitations exist due to an incomplete understanding of molecular pathways, particularly regarding TNF- α and IL-6's relation to osteoporosis, as well as the unclear role of IGF-1 in liver disease-related bone metabolism.

Heart-bone axis

Data from the World Health Organization indicates that cardiovascular diseases (CVDs), encompassing conditions such as atherosclerosis, myocardial obstruction, and ischemic heart disease, are the leading cause of mortality globally. Circulating endothelial progenitor stem cells (EPCs) derived from bone marrow have a complex bidirectional relationship with CVD (Fig. 2d). There is evidence suggesting that EPC markers, including TNF receptor superfamily member 4 (TNFRSF4/CD134), CD34 molecule (CD34), and vascular endothelial growth factor receptor [146], not only serve as indicators for CVD but also promote myocardial repair in the presence of ischemic injury [147]. Similarly, Rohde *et al.* [148] recently proposed that the cardiovascular system also impacts bone marrow.

Regarding the effects of bone on the cardiovascular system, Werner *et al.* [149] conducted a study involving 519 patients with coronary artery disease and predicted adverse

CVD based on the number of circulating CD34⁺ EPCs. Dimmeler *et al.*[150] suggested that the activation of the early apoptosis pathway in EPCs could signify the initial stage in the formation of atherosclerotic lesions and the development of heart failure in atherogenic arteries. These observations indicate a strong association between CVD and EPCs derived from bone marrow.

In terms of the interaction between the cardiovascular system and bone marrow, Rohde *et al.*[148] investigated how vascular endothelial cells in bone marrow relate to hematopoiesis in individuals with CVD. The researchers discovered an elevated level of hematopoiesis among individuals with hypertension, recent acute myocardial infarction, or both hypertension and atherosclerosis compared to healthy control individuals. Furthermore, there was a specific increase observed in immune cells derived from a subset of hematopoietic stem and progenitor cells known as myeloid progenitor cells.

The transplantation of BMSC-EVs into infarcted myocardium has emerged as a prominent area of research. Transplanting BMSCs into the heart results in the release of EVs that play a crucial role in cardioprotection and repair (Fig. 2d). Yu *et al.*[151] investigated the cardioprotective effects of EVs derived from BMSCs overexpressing GATA binding protein 4 in rats with myocardial infarction, revealing that treatment with these EVs injections reduced myocardial infarct size and increased miR-19a and miR-451 expression in cardiomyocytes. Feng *et al.*[152] found that miR-22, enriched in EVs secreted by MSCs, transferred to preconditioned rats cardiomyocytes experiencing cardiac ischemia, effectively mitigated ischemia-induced cardiomyocyte apoptosis by directly targeting methyl CpG-binding protein 2.

Additionally, Sun *et al.*[13] found an association between high circ-G042080 expression observed in several patients with primary myeloma-associated myocardial injury and reduced ventricular ejection fraction and systolic blood pressure, which are hallmarks of myocardial injury. This study suggests the potential of EVs mediating bone-cardiac communication. Moreover, Cheng *et al.*[153] investigated the role of mouse myocardial microRNAs in mediating functional crosstalk between the ischemic heart and bone marrow *via* circulating EVs, exploring their potential impact on cardiac repair. They revealed that after acute myocardial infarction, circulating EVs predominantly carry specific myocardial micro-RNAs such as miR-499, miR-133, miR-1, and miR-208 which are selectively imported into peripheral organs particularly the bone marrow, where they downregulate gene C-X-C motif chemokine receptor 4 (*CXCR4*) expression while increasing the number

of circulating progenitor cells.

In light of the existing literature, the heart-bone axis emerges as a complex yet underexplored domain with profound implications for cardiovascular and bone health. The factors can be categorized into three groups: 1) bone marrow-derived EPCs, which serve as markers and agents of myocardial repair in CVD, with CD34⁺ EPCs being predictive of adverse CVD outcomes; 2) vascular endothelial cells in the bone marrow, which influence hematopoiesis and myeloid cell production in CVD conditions; and 3) bone marrow-derived EVs, which play a role in cardiac repair through the transfer of microRNAs and other molecules. The advantages for clinical applications include the potential use of EPCs and bone marrow-derived EVs in myocardial repair, as well as the use of cellular markers for predicting and managing CVD. However, there are also disadvantages such as the complex and incompletely understood interaction mechanisms between the heart and the bone marrow, along with variability in patient responses. Therefore, we call for a more integrated approach to studying the heartbone axis by incorporating advanced molecular techniques and multi-omics analyses. We also highlight the potential therapeutic targets such as the modulation of specific microRNAs or using EVs for targeted drug delivery. This summary underscores the intricate bidirectional relationship between the heart and bone while emphasizing how bone marrow-derived cells and EVs hold promise in treating CVD.

Kidney-bone axis

Kidney to bone

Renal effects on the bone are now generally focused on mineral and bone disease (MBD) resulting from chronic kidney disease (CKD). MBD in CKD is a physiological imbalance of calcium, phosphate, and parathyroid hormone (PTH) due to abnormal renal metabolism (Fig. 2e). Specifically, as glomerular filtration performance decreases, there is a reduction in renal tubule reabsorption levels and phosphate reabsorption, resulting in elevated serum phosphate concentrations[154]. Increased phosphate levels stimulate osteoblasts to secrete FGF-23, thereby increasing PTH levels[155-157]. Clinically, hypocalcemia is commonly observed in CKD patients, which further promotes PTH hyperactivity[157]. A recent study also suggests that the increased secretion of FGF-23 by osteocytes is influenced by the elevation of glycerol-3-phosphate in CKD[158]. FGF-23 also inhibits the active form of vitamin D, subsequently impacting PTH elevation[159]. Eventually, the elevations in FGF-23 and PTH aggravate bone resorption and disrupt bone homeostasis resulting in MBD[160,161]. In cases of kidney injury, activin A is upregulated in the blood, positively affecting renal cell fibrosis[162]. In mouse models,

inhibition of activin A secretion contributes to kidney injury repair[163]. In bone, activin A is secreted by osteolineage cells and abundantly presents in the extracellular matrix (ECM). Although it has multiple effects on bone physiology involving various cell types, it is generally considered a negative regulator of bone formation[164].

Bone to kidney

The bone mainly affects the kidney through FGF-23, which inhibits phosphate reabsorption in renal tubules by suppressing the expression of renal phosphate transporters within renal proximal tubules[165]. Additionally, FGF-23 hinders the expression of 1- α hydroxylase in the renal proximal tubule while stimulating 24-hydroxylase. This enzyme converts 25-OH vitamin D and calcitriol into inactive substances[165,166]. Moreover, a recent study identified immature myeloid cells in the bone marrow as a significant cellular source of soluble plasminogen activator, urokinase receptor, a circulating biomarker of inflammation that significantly impacts kidney disease pathogenesis[167].

In preclinical and clinical studies, BMSCs have been confirmed to possess substantial therapeutic effects on kidney diseases such as acute kidney injury (AKI) and CKD (Fig. 2e). Shen *et al.*[168] investigated the potential therapeutic role of C-C motif chemokine receptor 2 (CCR2) in BMSC-EVs concerning ischemia/reperfusion kidney injury. They demonstrated that CCR2 has a high affinity for its ligand, C-C motif chemokine ligand 2 (CCL2), and that CCR2-positive EVs could decrease free CCL2 levels, inhibit its recruitment or activation of macrophages, and significantly impact inflammatory regulation and renal injury repair. Mice with renal ischemia-reperfusion injury were administered CCR2 knockout BMSC-EVs resulting in impaired reparative effects.

Cao *et al.* [169] demonstrated the therapeutic effect of miR-200a-3p in BMSC-EVs on acute kidney ischemia-reperfusion injury and its underlying mechanism. Specifically, in the AKI model mice, miR-200a-3p downregulated kelch-like ECH-associated protein 1 expression and inhibited the upregulation of nuclear factor erythroid 2-related factor 2 and superoxide dismutase 2 while regulating mitochondria to exert antioxidant effects for renal damage repair. Tapparo *et al.*[170] utilized microRNA-enriched EVs from different species to treat an AKI model by assessing renal function and morphology. They performed bioinformatic analysis and identified that miR-127-3p, miR-29a-3p, miR-10a-5p, and miR-486-5p as crucial factors in renal injury repair. Among them, miR-486-5p was found to be the most abundant microRNA in the exosomal fraction, demonstrating its superior efficacy in promoting AKI recovery.

Bruno *et al.*[171] discovered that BMSC-EVs carry specific

mRNAs [cyclin B1 (*CCNB1*), cyclin-dependent kinase 8 (*CDK8*), and cell division cycle 6 (*CDC6*)], which contribute to their pro-proliferative effect on mouse renal tubular epithelial cells both *in vitro* and *in vivo*. Wang *et al.*[172] reported the successful delivery of miR-let7c to damaged kidneys in mice with unilateral ureteral obstruction using engineered BMSCs. The therapy with miR-let7c reduced kidney injury by downregulating the expression levels of collagen type IV alpha 1 (*Col4a1*), matrix metalloproteinase-9 (*Mmp-9*), transforming growth factor (TGF) beta 1 (*Tgfb1*), and TGF beta receptor 1 (*Tgfbr1*) in the kidneys of mice with unilateral ureteral obstruction.

The kidney-bone axis represents a compelling paradigm of endocrine interplay, particularly in the context of CKD and MBD. While the role of FGF-23 and PTH in modulating bone and renal physiology is well documented, the precise mechanisms and potential therapeutic targets remain an active area of research. For example, recent findings on the role of glycerol-3-phosphate in elevating FGF-23 levels in CKD offer a new avenue for intervention, but further validation is needed. Similarly, the therapeutic potential of BMSC-EVs in renal diseases is promising but not yet universally accepted due to the heterogeneity in study designs and outcomes. The clinical importance of understanding the kidney-bone axis cannot be overstated, especially given the high prevalence of CKD and associated comorbidities such as MBD. The potential for targeted therapies, such as modulating specific microRNAs or using EVs for drug delivery, offers tantalizing prospects for personalized medicine. However, these therapeutic avenues also necessitate a more nuanced understanding of the underlying molecular mechanisms, possibly through multi-omics approaches and machine learning algorithms for data integration.

Muscle-bone axis

Muscle to bone

In the context of inflammation and aging, elevated secretion of IL-6 from skeletal muscle exerts its effects on bone through the circulatory system, leading to the induction of osteoclast formation[173]. Myostatin (MSTN), a protein secreted by muscle cells, stimulates RANKL expression to enhance osteoclast activity[174]. Regarding bone metabolism, FGF-21, an actin associated with glucose and lipid metabolism, inhibits osteocyte proliferation and bone marrow adipogenesis[130] (Fig. 3a).

Irisin enhances osteoblast activity by triggering the activation of transcription factor 4, thereby positively influencing bone health[175,176]. Another myokine called β -aminoisobutyric acid (β -aa), is elevated during exercise and

acts as an antioxidant to safeguard osteocytes against oxidative stress to prevent bone resorption[177]. Meteorin-like, another myo-factor, inhibits bone resorption by attenuating pro-

inflammatory cytokines such as IL-6 and TNF- α . Furthermore, IGF-1 and FGF-2 are both growth factors produced by skeletal muscle, promoting osteoblast formation and thus enhancing




Fig. 3 The systemic integration of bone-organ signaling axes.

This figure maps the multidirectional signaling networks that connect bone with muscle, adipose tissue, gonads, intestine, pancreas, and thyroid, focusing on the molecular mediators involved in these interactions. a. The bone-muscle axis is characterized by a reciprocal regulatory network, where cytokines, growth factors, and EVs such as IL-6, MSTN, and miR-218 influence myogenesis and osteogenesis, illustrating the integral role of muscle in bone homeostasis; b. The bone-adipocyte axis delves into the metabolic crosstalk through adipokines and osteokines, highlighting the dual role of fatty acids and hormones such as leptin in energy metabolism and bone remodeling. The bone-ovary (c) and bone-testis (d) axes detail the endocrine interplay, with estrogen and testosterone being pivotal regulators of bone density and gonadal function, underscoring the importance of sex hormones in skeletal integrity; e. The bone-intestine axis emphasizes the regulatory roles of intestine-derived immune signals, microbiota byproducts, and probiotics on bone health; f. The bone-pancreas axis highlights the insulin-OCN feedback loop essential for energy metabolism and bone density regulation; g. The bone-thyroid axis demonstrates the thyroid hormones' direct impact on bone growth and metabolism. Collectively, these axes not only dictate the physiological regulation of bone density and turnover but also highlight the systemic implications of bone as a central organ in orchestrating overall homeostasis. IL-1/6. Interleukin-1/6; MSTN. Myostatin; β -aa. β -aminoisobutyric acid; IGF-1. Insulin-like growth factor-1; FGF-21. Fibroblast growth factor-21; TNF- α . Tumor necrosis factor- α ; OCN. Osteocalcin; SOST. Sclerostin; TGF- β . Transforming growth factor- β ; RANKL. Receptor activator of nuclear factor kappa-B ligand; INSL3. Insulin-like 3; CYP2R1. Cytochrome P450 family 2 subfamily R member 1; Th17. T helper 17 cells 17; NOD1/2. Nucleotide-binding oligomerization domain 1/2; SCFAs. Short-chain fatty acids; TNO. Trimethylamine-N-oxide; Try. Tryptophan; KYN. Kynurenine; TLR5. Toll-like receptor 5; TH. Thyroid hormone

overall bone metabolism[178,179] (Fig. 3a).

Muscle-derived EVs have been shown to promote osteogenic differentiation in MC3T3-E1 cells through the β -catenin signaling pathway to the bone, as demonstrated by Xu *et al.*[180]. Specifically, EVs derived from C2C12 myoblasts or myotubes were found to enhance this process, with miR-27a identified as the primary functional factor. Furthermore, miR-27a has been implicated in enhancing myoblast differentiation[181,182], and its mimic has shown potential in alleviating the muscle atrophy induced by CKD[183]. These findings collectively suggest that miR-27a may play a crucial role in mediating the communication between muscle-derived EVs and bone.

Recently, a fascinating study showed that miR-34a is significantly upregulated in skeletal muscle and serum EVs from aged mice. Fulzele *et al.*[184] reported an age-related increase in miR-34a levels in EVs positive for sarcoglycan α or derived from oxidatively stressed C2C12 cells. Importantly, these EVs were found to migrate to the bone marrow, where they induced BMSC senescence by suppressing the expression of sirtuin 1 (*Sirt1*). The elevated levels of miR-34a in aging muscle may contribute to muscle metabolic dysfunction, while reduced SIRT1 activity in aging muscle was associated with impaired muscle performance[185,186].

Furthermore, MSTN was observed to suppress osteocyte-derived EVs containing miR-218, which were subsequently internalized by osteoblasts and hindered their differentiation[174]. MSTN also decreased the levels of miR-218 in EVs derived from both osteocytes and their parent cells. Notably, miR-218 was found to enhance the Wnt pathway by inhibiting *SOFT* expression. Specifically, EVs released by Ocy454 osteocytes treated with MSTN could be internalized by osteoblast and osteoclast precursor cells *in vitro*. These EVs then inhibited osteoblastic differentiation through modulation of the Wnt pathway, although they did not influence osteoclastic differentiation[174]. It is important to note that these conclusions are based on findings obtained through *in vitro* experiments and further studies conducted *in vivo* are warranted.

Bone to muscle

In this section, the effects of muscle on bone are described in terms of OCN, SOST, prostaglandin E2 (PGE2), TGF- β , RANKL, and EVs (Fig. 3a). OCN expression levels have been reported to increase during exercise but decline with age[187]. OCN secreted by end-stage osteoclasts can interact with the muscle receptor G protein-coupled receptor family C group 6 member A (GPCR6) to regulate muscle function[188]. Under pathological conditions, TGF- β released by the bone matrix reduces muscle strength by decreasing Ca^{2+}

levels[189]. Moreover, OCN promotes IL-6 expression, which subsequently stimulates OCN expression in bone, positively affecting muscle growth. SOST secreted by osteocytes impedes bone formation through the canonical Wnt/ β -catenin pathway[190]. Deficiency of SOST induced by *SOST* gene deletion or administration of SOST antibodies not only increases bone mass[191] but may also lead to sclerosteosis development[192]. Conversely, SOST expression decreases after bone or muscle loading[193,194].

Furthermore, PGE2 is vital in enhancing the functionality of skeletal muscle-specific stem cells, leading to improved regeneration and strength through its interaction with the prostaglandin E receptor 4 (PTGER4)[195]. Additionally, PGE2 activated the β -catenin pathway by stimulating PI3K in osteocytes[196], and it promoted the proliferation of C2C12 myoblasts[197]. The signaling of PGE2 mitigates muscle atrophy and revitalizes muscle function. Therefore, targeting the PGE2-degrading enzyme 15-prostaglandin dehydrogenase could be a promising therapeutic strategy for preventing sarcopenia[198].

Produced by the bone matrix, TGF- β is another regulatory factor that significantly influences muscle growth. Treatment with TGF- β reduced specific muscle force but did not affect muscle mass in mice[199]. Moreover, TGF- β induced muscle weakness in mice with osteolytic cancer by elevating oxidative stress and causing calcium mishandling within muscles[189,200]. RANKL also plays a pivotal role in mediating osteoclast formation, function, and survival [201]. Excessive expression of RANKL leads to bone loss and reduced muscle performance. Deletion of the RANKL receptor in muscles prevents denervation-induced muscle atrophy and dysfunction[202]. Treatment with anti-RANKL agents such as denosumab protects against skeletal muscle dysfunction while enhancing bone mechanical properties[203]. Notably, denosumab substantially augmented appendicular lean mass and enhanced handgrip strength, implying a close relationship between bone and muscle while suggesting denosumab as a potential innovative treatment for sarcopenia[204].

The muscle-bone axis is a critical interface for the interplay of various signaling molecules, growth factors, and EVs, orchestrating a complex regulatory network that profoundly impacts musculoskeletal health and disease. While the inhibitory roles of IL-6, MSTN, and FGF-21 in bone formation are well-established, emerging data on the beneficial effects of irisin and β -aa present new avenues for therapeutic interventions. The modulation of this axis by EVs, particularly those containing miR-27a and miR-34a, is an expanding field that necessitates further investigation. Understanding

the clinical relevance of the muscle-bone axis is paramount, especially in the aging population where sarcopenia and osteoporosis often coexist. Targeted therapies, such as anti-RANKL treatment and modulating PGE2 signaling hold potential but require rigorous clinical validation. Furthermore, exploring the role of EVs in this axis could revolutionize our understanding and offer novel therapeutic strategies. However, it is crucial to acknowledge that most of the current knowledge stems from *in vitro* studies and animal models, thus translational research is imperative to validate these findings in humans.

Adipocyte-bone axis

Adipose tissue to bone

Adipose tissue exerts its influence on bone through four mechanisms. Firstly, adipocytes release endocrine cytokines and growth factors that impact the function of osteoblasts and osteoclasts. Secondly, adipokines such as leptin and adiponectin regulate the sympathetic outflow from the CNS. Thirdly, paracrine factors produced by adipocytes within the bone marrow microenvironment affect neighboring cells in trabecular bone. Lastly, EVs derived from adipose tissue play a role in modulating bone physiology, pathology, and disease treatment differentially (Fig. 3b).

Regarding the endocrine influence of adipose tissue, visceral fat depots characterized by inflammation release cytokines such as resistin, TNF- α , IL-1, and IL-6. These cytokines disrupt bone remodeling by promoting bone resorption or inhibiting bone formation[205]. Similarly, both adiponectin and leptin have the potential to affect bone remodeling either through endocrine actions or by influencing the hypothalamic centers that regulate sympathetic activity[206-208]. The release of sympathetic impulses impedes osteoblast differentiation and promotes osteoclast recruitment, leading to the uncoupling of the bone remodeling unit.

Concerning the paracrine effects of adipose tissue, bone marrow adipocytes, which were initially discovered more than a century ago, constitute an essential component of the bone marrow environment and play a crucial role in both skeletal function and hematopoiesis[209]. Moreover, osteoblasts and adipocytes originate from common precursor MSCs, making their differentiation pathways closely interconnected[210]. The differentiation process of MSCs into either adipocytes or osteoblasts is highly regulated and involves various lineage-specific transcription factors. For example, RUNX2 and OSX are pivotal in promoting osteoblast differentiation, while peroxisome proliferator-activated receptor gamma (PPARG) plays a critical role in driving adipocyte differentiation[211]. Notably, inhibiting PPARG promotes osteogenesis

while increasing PPARG activity reduces it, indicating a potentially mutually exclusive relationship between these two processes[212]. Additionally, the elevated production of adipose-related factors such as fatty acids can exert both positive and negative effects on metabolism within the bone marrow depending on the specific fatty acid involved and the type of receptor activation on BMSCs[213].

Adipose tissue-derived EVs play an important role in bone remodeling by regulating the function of osteoclasts and osteoblasts. Table 2 lists the microRNAs associated with obesity and osteoporosis as potential targets[214]. Interestingly, the release of EVs from white adipose tissue increases while that from brown adipose tissue decreases in osteoporosis. Furthermore, adipose tissue-derived EVs have been implicated as pivotal drivers of multiple myeloma (MM) tumorigenesis and disease progression, particularly through miR-181a and miR-181b which are also linked to adipose tissue and BMSCs[215]. Therefore, the exchange of EVs between bone marrow adipose tissue and MM cells mediated by these microRNAs[16] represents a promising mechanism supporting the progression of MM. Moreover, studies have found that adipose tissue-derived EVs regulate osteogenic differentiation and promote bone regeneration *in vivo*. Chen *et al.*[216] used miR-375-enriched stem cells derived from adipose tissue to improve the osteogenic differentiation of human BMSCs and new bone formation in a rat model.

Bone to adipose tissue

The OCN-insulin-fat axis exerts an influence on adipose tissue, whereby under normal conditions, adipose tissue displays high insulin sensitivity but becomes a source of insulin resistance[217] (Fig. 3b). However, obesity is associated with several significant health issues, including hypertension, diabetes mellitus, and dyslipidemia, which are the ominous triad linked to insulin resistance. Obesity leads to increased energy metabolism in adipocytes, thereby contributing to these health issues[20].

The interplay between adipocytes and bone involves complex endocrine, paracrine, and autocrine mechanisms. Adipokines such as leptin and adiponectin play a role in modulating bone remodeling through CNS pathways, adding another layer of complexity. Additionally, the emerging frontier of research focuses on the impact of adipose tissue-derived EVs, particularly those enriched in miR-181a and miR-181b, on osteogenic differentiation and tumorigenesis in MM, offering potential novel therapeutic avenues. Understanding this axis holds clinical significance due to the increasing prevalence of obesity and metabolic syndrome, which are intrinsically linked with bone health. Targeting key regulators like PPARG

Table 2 Target microRNAs associated with obesity and osteoporosis

EVs	Expression in OP patients	Expression in obesity patients	Function
White adipose tissue-derived EVs			
miR-133a	↑	↓	Promotes osteoclast differentiation and inhibits osteoblast differentiation
miR-146	↑	↑	Inhibits osteogenesis
miR-155	↑	↑	Inhibits osteogenesis
miR-214	↑	↑	Inhibits osteogenesis
miR-125a	↑	↑	Promotes osteoclast differentiation
miR-23	↑	↑	Inhibits osteogenesis
miR-548	↑	↑	Unknown
miR-488	↑	↑	Inhibits osteogenesis
miR-27a	↑	↑	Inhibits osteogenesis
miR-122a	↑	↑	Inhibits osteogenesis
miR-194	↑	↑	Inhibits osteogenesis
miR-22	↑	↑	Inhibits osteogenesis
Brown adipose tissue-derived EVs			
miR-365	↓		Ameliorates dexamethasone-induced suppression of osteogenesis
miR-1	↓		Stimulates osteogenesis and inhibits adipogenesis
miR-874	↓		Promotes the proliferation and differentiation of osteoblasts
miR-455-3p	↓		Protects osteoblasts from oxidative stress
miR-378	↓		Inhibits osteoclastogenesis
miR-193	↓		Ameliorates bone resorption
miR-29a	↓		Represses osteoclast formation
miR-199a	↓		Promotes osteogenic differentiation

EVs. Extracellular vesicles; OP. Osteoporosis

could provide dual benefits by promoting osteogenesis while inhibiting adipogenesis, thus addressing both aspects of the axis effectively. Moreover, exploring the role of adipose tissue-derived EVs in bone remodeling and disease progression opens up new possibilities for targeted therapies specifically for conditions such as osteoporosis and MM.

Ovary-bone axis

The primary role of the ovaries in bone metabolism is to secrete estrogen, which directly impacts osteoblasts, osteoclasts, and osteocytes. This disrupts the equilibrium of bone remodeling by promoting bone formation and reducing bone resorption[218] (Fig. 3c). Deficiency of estrogen receptor 1 (ESR1/ER α) specifically in osteoblasts and significantly decreased estrogen levels leads to a reduction in bone trabeculae. Firstly, estrogen impedes RANKL/colony-stimulating factor 1-induced AP-1-dependent transcription by reducing c-Jun expression and phosphorylation. Estrogen also inhibits RANKL-induced osteoclast differentiation[218]. Moreover, estrogen inhibits RANKL-stimulated osteoclastic differentiation by facilitating

the complex formation between ER α and breast cancer anti-estrogen resistance 1 (BCAR1). The ER α /BCAR1 complex then sequesters TNF receptor-associated factor 6, leading to reduced NF- κ B activation and impaired RANKL-induced osteoclastogenesis[219]. Estrogen has been shown to prolong the lifespan of osteoblasts and inhibit osteoblast apoptosis[220]. At the molecular level, this effect is attributed to estrogen's activation of the proto-oncogene non-receptor tyrosine kinase (SRC)/adaptor protein 1 (SHC1/SHC)/extracellular signal-regulated kinase (ERK) signaling pathway[220]. Additionally, it involves the downregulation of JNK, which in turn affects the activity of various transcription factors, including cyclic adenosine monophosphate (cAMP)-response element binding protein, CCAAT enhancer binding protein-beta, ETS transcription factor ELK1, and c-Jun/Fos proto-oncogene AP-1 transcription factor subunit[221].

Testis-bone axis

Testis to bone

Testosterone, secreted by the testes, is the primary hormone in males and plays a crucial role in bone metabolism.

Androgens bind to androgen receptors on osteoblasts, osteoclasts, osteocytes, and growth plate chondrocytes, to inhibit trabecular bone resorption and maintain bone homeostasis[222,223]. The impact of testicular function on bone metabolism also relies on the production of two key factors by Leydig cells: insulinlike 3 (INSL3) and cytochrome P450 family 2 subfamily R member 1 (CYP2R1) (Fig. 3d). Specifically, Ferlin *et al.*[224] elucidated the precise molecular mechanism through which INSL3 exerts its anabolic effects on osteoblasts. When INSL3 activates the G-protein coupled relaxin family peptide receptor 2 (RXFP2), it initiates a cascade of events including elevation of cAMP levels, activation of the mitogen-activated protein kinase (MAPK) cascade, and upregulation of essential osteoblast genes crucial for osteoblast differentiation, matrix deposition, and osteoclastogenesis, leading to mineralization induction[225]. Additionally, CYP2R1 inactivation in Leydig cells suppresses the expression of 25-hydroxylase[225].

Bone to testis

The testicular Leydig cells are primarily influenced by the binding of OCN secreted by osteoblasts to the G protein-coupled receptor class C group 6 member A (Fig. 3d), leading to a positive regulatory effect on testosterone secretion. Specifically, bone exerts its influence through OCN, an osteoblast-derived hormone that binds to specific receptors on Leydig cells and promotes testosterone biosynthesis[226].

The ovary-bone and testis-bone axes represent pivotal hormonal pathways that significantly impact bone metabolism. Estrogen and testosterone, which are the primary hormones secreted by the ovaries and testes, respectively, act as key regulators of osteoblast and osteoclast activity. These axes involve intricate molecular mechanisms such as estrogen signaling mediated by the ER α /BCAR1 complex and testicular function regulated by RXFP2 activation through INSL3. Hormone replacement therapies, already established for postmenopausal osteoporosis treatment, could be further improved by targeting specific molecular pathways such as SRC/SHC/ERK for estrogen or cAMP and MAPK cascades for INSL3. Moreover, the role of vitamin D metabolism, influenced by CYP2R1 in Leydig cells, opens up additional avenues for intervention. However, it is crucial to note that while these hormonal axes offer promising therapeutic targets, they also carry potential risks such as hormone-dependent cancers. Therefore, a nuanced approach considering both the benefits and risks is essential when translating these molecular insights into clinical practice.

Intestine-bone axis

The gut microbiota (GM), consisting of trillions of

microorganisms residing in the intestine and establishing mutually beneficial relationships with the host, primarily influences bone through the intestinal tract[227,228]. The GM exerts its impact on various physiological processes of the host, including growth, energy metabolism, immune function, and inflammatory processes. Moreover, through nutrient production and absorption, immune regulation, metabolite release, systemic inflammation modulation as well as metabolite generation (Fig. 3e), the GM significantly contributes to the regulation of bone remodeling. Recent studies have shown that the GM potentially regulates bone metabolism by modulating the host's immune status. Specifically, there is an association between bone metabolism and the balance between Th17 cells [CD4 molecule (CD4)⁺, IL-17A⁺] and T regulatory (Treg) cells [CD4⁺, CD25⁺, forkhead protein P3 (FOXP3)⁺][229,230]. Th17 cells are a subset of CD4⁺ T cells that become activated and migrate to the bone stroma where they produce IL-17 to enhance regional inflammation. This elevation in inflammatory cytokines such as TNF- α and IL-6 promotes RANKL expression while activating osteoblast precursor cells to facilitate osteoblast differentiation[229,231]. On the other hand, Treg cells remain stable in the intestinal mucosa with their development being promoted by several bacteria including *Clostridium*[232], *Bacteroides*[233], *Bifidobacterium*[234], *Lactobacillus*[233], and *Helicobacter*[235]. Among them, the CD4⁺CD25⁺FOXP3⁺ Treg cells suppress T-cell activation through a cytotoxic T lymphocyte-related protein 4-mediated pathway, which reduces the expression of RANKL along with other cytokines thereby inhibiting osteoclast differentiation leading to attenuation of bone resorption while promoting bone formation.

Moreover, increasing evidence emphasizes the significance of the interplay between the GM and bone through innate immune signaling pathways involving receptors such as nucleotide-binding oligomerization domain containing 1/2 (NOD1/2) and TLR5. Germ-free mice lacking NOD1 or NOD2 do not exhibit the typical increase in bone mass or decrease in TNF- α and RANKL expression observed in mice with intestine colonization, suggesting that NOD1 and NOD2 signaling are crucial for the interaction between microbes and bone[236]. TLR5 is known to activate RANKL expression and promote osteoclast formation[237].

Furthermore, the GM produces metabolites that affect bone metabolism, such as short-chain fatty acids (SCFAs; e.g., acetate, butyrate, and propionate), trimethylamine-N-oxide (TNO), and tryptophan (Try). SCFAs not only foster regulatory T-cell development[238,239] but also suppress Th17 cell generation in the small intestine[240,241]. They

also decrease the production of inflammatory cytokines, including IL-23, IL-17, and IL-6[240,241], contributing to systemic immune homeostasis. Moreover, SCFAs inhibit osteoclast formation by inhibiting HDACs essential for human osteoclastic bone formation[242-244]. SCFAs are vital in bone formation and mineralization by modulating the OPG and Wnt signaling pathways[245,246].

TNO, a GM-dependent metabolite derived from trimethylamine, not only promotes adipogenesis in BMSCs and reduces osteogenesis but also upregulates the expression of proinflammatory cytokines (e.g., IL-1 β , IL-6, and TNF- α) and reactive oxygen species[247]. Moreover, Try metabolites, particularly kynurenine (KYN) and serotonin, are closely associated with bone metabolism. KYN has been specifically demonstrated to impact BMSC proliferation by directing them toward the osteoblastic cell lineage[248,249]. Additionally, both osteoblasts and osteocytes possess serotonin receptors[250] that stimulate osteoblast proliferation while inhibiting osteoclast formation upon serotonin binding to these receptors[251].

Probiotics are living microorganisms that exert positive effects on the host's health when consumed in specific quantities, and they are anticipated to be utilized for the modification of bone disease[252]. *Bacteroides vulgatus* ATCC 8482 inhibited intestinal dysbiosis and downregulated the colonic interferon regulatory factor 6/TLR4/NF- κ B pathway, thereby reducing serum TNF- α levels[253]. Similarly, administration of a combination of *Lactobacillus plantarum* NK3 and *Bifidobacterium longum* NK49 suppressed the NF- κ B/TNF- α pathway[254]. All three bacteria have shown potential in promoting bone formation. Probiotics have also demonstrated efficacy in preventing bone loss in animal models such as rats and zebrafish[255,256]. *In vitro* experiments have further revealed that exposure to *Lactobacillus plantarum* GKM3 and *Lactobacillus paracasei* GKS6 significantly upregulates the expression of osteoblast-related marker genes while downregulating the expression of osteoclast-related genes[257]. Clinical trials have indicated that long-term probiotic supplementation in postmenopausal women reduces serum markers related to bone resorption, thus contributing to alleviating bone resorption[258,259]. *Akkermansia muciniphila* promotes fracture healing by decreasing intestinal permeability and attenuating inflammatory responses, inducing the release of platelet-derived growth factor-BB, and facilitating H-vessel formation in bone scar tissue[260].

Pancreas-bone axis

Pancreas to bone

Osteoblasts are rich in insulin receptors (INSR) that bind with

insulin to regulate bone metabolism (Fig. 3f). Specifically, β -cells in the pancreas secrete insulin, which can interact with the INSR in osteoblasts. Insulin signaling in osteoblasts has the ability to suppress gene expression and promote OCN expression[261]. EVs released by pancreatic cancer cells can transfer microRNAs and other RNAs to bone marrow cells, leading to the downregulation of transcription factor genes associated with the differentiation, polarization, cytokine production, and migration of monocytes and macrophages in the bone marrow. Consequently, this transfer process influences the functionality and metabolic activity of bone marrow cells, ultimately contributing to the establishment of a tumor-promoting microenvironment[262].

Bone to pancreas

There are two forms of OCN, fully carboxylated and incompletely carboxylated, which exert their regulatory effects on the pancreas to modulate β -cell and insulin secretion (Fig. 3f). Specifically, OCN functions as a hormone that promotes the proliferation of β -cells and enhances both insulin expression and secretion. OCN also augments insulin sensitivity and promotes energy expenditure[20,263].

Thyroid-bone axis

The thyroid primarily affects bone through the secretion of thyroid hormone (TH), which exists in two forms: 3,5,30-L-triiodothyronine (T3) and 3,5,30,50-tetraiodothyronine (thyroxine, T4). T4 is predominantly secreted by the thyroid gland, whereas T3 is mainly derived from the conversion of T4 by type 1 deiodinase in the liver, although a small amount is also secreted by the thyroid gland itself. TH plays a precise regulatory role in bone metabolism, and its deficiency or excessive activity can lead to bone defects (Fig. 3g). Specifically, TH exerts its effects on bone primarily through nuclear TH receptor beta (THR β /TR β), which exhibits an expression level in skeletal tissues more than 10-time higher than that of nuclear TH receptor alpha (THRA/TR α)[264,265].

Numerous studies conducted on mice have revealed that those with TR α deficiency or mutation maintain euthyroid status systemically but display phenotypic characteristics resembling juvenile hypothyroidism such as reduced bone formation and decreased BMD[265,266]. Young mice with TR β deletions or mutations exhibit typical hyperthyroidism-induced effects on bone resulting in a short stature phenotype[266]. Similarly, adult mice with TR α deficiency or mutation remain euthyroid systemically but demonstrate a significant increase in trabecular volume and mineralization due to a net decrease in osteoclast absorption of bones[265]. In contrast, adult mice with TR β mutation

experience increased osteoclast absorption of bones and severe osteoporosis due to the effects of hyperthyroidism on skeletal cells expressing TR α [265].

In clinical practice, hypothyroidism in mature individuals leads to decreased bone turnover and impaired osteoclast-mediated bone resorption as well as osteoblast-driven bone formation[267]. Simultaneously, the prolongation of the bone remodeling cycle contributes to prolonged secondary mineralization, thereby increasing the susceptibility to fractures in patients[268,269]. Furthermore, individuals with thyrotoxicosis and hyperthyroidism exhibit an increased risk of fragility fractures, reduced BMD, and osteoporosis[267,269].

The intricate interplay between various organ systems and bone metabolism is highlighted by the axes of intestine-bone, pancreas-bone, and thyroid-bone. For example, the GM not only influences nutrient absorption but also modulates immune responses that can either promote or inhibit bone resorption. Similarly, insulin from the pancreas and TH, directly and indirectly, impacts bone homeostasis by affecting both osteoblast and osteoclast activity. The potential of intestine-bone axis in modulating bone health through dietary interventions or probiotic supplementation is particularly intriguing, targeting specific microbiota such as *Clostridium* or *Bacteroides* that promote Treg cell development. The pancreas-bone axis offers a compelling avenue for understanding the metabolic underpinnings of bone health, especially in relation to diabetes and pancreatic cancer. With its well-defined hormonal pathways, the thyroid-bone axis provides a robust framework for therapeutic interventions, particularly for conditions like hyperthyroidism that lead to bone loss. However, it is crucial to consider the multifactorial nature of bone metabolism as single-axis interventions may not yield the desired outcomes due to compensatory mechanisms in other axes. Therefore, adopting a holistic multitargeted approach may prove more effective.

Summary of bone-organ axes

The understanding of bone-organ crosstalk has significantly advanced in recent years. This process can be traced back to the discovery of osteokines, which are cytokines secreted by bone and act as communication agents with distant organs. This concept originated from the identification of specific osteokines and their effects on various organs, such as the kidneys, pancreas, and cardiovascular system (Fig. 4a). The list of osteokines continues to expand, with notable ones including FGF-23, SOST, and OCN. Concurrently, the role of bone as a responsive organ has been highlighted, with various tissues influencing bone homeostasis through their

secretion of cytokines. For example, MSTN from muscles and leptin from adipose tissues have significant impacts on bone physiology[270]. Notably, several osteokines exhibit autocrine effects on the bone itself. The exploration of bone-derived factors and their roles in health and disease is ongoing. Currently, there is a primary focus on investigating the roles of osteokines in mediating communication between bone and other organs as well as their implications in skeletal disorders, metabolic diseases, and aging processes. Discovering novel osteokines and understanding their specific functions could potentially pave new paths for therapeutic interventions targeting these diseases. Furthermore, the identification of these osteokines could serve as valuable biomarkers for monitoring various physiological responses and disease progression.

In addition, the perspective on cellular communication and the role of EVs have significantly evolved in recent years. EVs carry a complex cargo consisting of proteins, lipids, and nucleic acids, which reflect their originating cell and convey information to recipient cells[271]. This concept was further reinforced by the discovery of EVs involvement in various physiological and pathological processes, such as angiogenesis, cancer metastasis, and immune responses. Emerging research has identified numerous EV-associated molecules, including specific microRNAs, proteins, and lipids[272]. Moreover, the role of EVs extends to various organs through autocrine, paracrine, or endocrine mechanisms facilitating intricate interactions between cells within both local and distant organs[6,273]. Bone-derived EVs are known to interact with the immune system, kidneys, and even the CNS (Fig. 4b). Recently discovered exercise-induced EVs suggest their potential role in mediating some systemic benefits derived from physical activity. Despite the predominant focus on studying EVs in cancer biology and immune responses, exploring their significance in exercise physiology and organ crosstalk is an emerging field of interest[274]. It is imperative to investigate methods for determining specific vesicle origins while elucidating their precise actions and mechanisms when targeting different organs *in vivo*. Identifying novel EVs-associated molecule specificities and their specific roles could lead to groundbreaking therapeutic targets as well as diagnostic tools for various diseases, thereby revolutionizing our comprehension of intercellular communication dynamics alongside systemic homeostasis.

Implications for bone-on-chips and assembloids

As previously mentioned, significant achievements have been made in understanding the bidirectional communication




Fig. 4 (See legend on next page.)

(See figure on previous page.)

Fig. 4 The bidirectional bone-organ crosstalk mediated by osteokines and extracellular vesicles (EVs).

a. The central role of bones in the complex process of interorgan dialogue illustrates the osteokine network that intricately links bone physiology to distal organ systems. The hormone testosterone, for instance, flows from the testis to the bone, influencing its density, while bone-derived OCN reciprocates by guiding muscle metabolism. The illustration also highlights how the kidneys modulate bone health through mineral balance and how the bone, in return, affects renal function through FGF-23. The brain, heart, and adipose tissue are similarly intertwined with bone through their respective hormonal and cytokine emissaries, creating a dynamic equilibrium essential for maintaining overall body health; b. The figure illustrates the role of EVs in traversing the body, carrying cargoes with potential therapeutic implications for heart, liver, lung, and other diseases. The figure also depicts how EVs from the brain, muscle, kidney, lung, and fat cells directly influence the bone formation process under both physiological and pathological conditions. Collectively, these visual representations elucidate the complex communication networks in which osteokines and EVs are crucial, orchestrating bidirectional bone-organ crosstalk that maintains physiological homeostasis and responds to pathological challenges. GnRH. Gonadotropin-releasing hormone; GHRH. Growth hormone-releasing hormone; TRH. Thyrotropin-releasing hormone; CRH. Corticotropin-releasing factor; NPY. Neuropeptide Y; CART. Cocaine amphetamine-regulated transcript; 5-HT. 5-hydroxytryptamine; SEMA4D. Semaphoring 4D; SEMA3A. Semaphoring 3A; POMC. Proopiomelanocortin; NMU. Neuromedin U; DA. Dopamine; Glu. Glutamate; CB. Cannabinoid; OCN. Osteocalcin; LCN2. Lipocalin 2; DKK1. Dickkopf 1; SOST. Sclerostin; GH. Growth hormone; TSH. Thyroid stimulating hormone; FSH. Follicle-stimulating hormone; ACTH. Adrenocorticotrophic hormone; IL-1/6/8. Interleukin-1/6/8; TNF- α . Tumor necrosis factor- α ; BMP-9. Bone morphogenetic protein-9; IGF-1. Insulin-like growth factor-1; LCAT. Lecithin-cholesterol acyltransferase; RANKL. Receptor activator of nuclear factor kappa-B ligand; OPG. Osteoprotegerin; sRAGE. Soluble receptors for advanced glycation end products; PTH. Parathyroid hormone; FGF-21/23. Fibroblast growth factor-21/23; EVs. Extracellular vesicles; MSTN. Myostatin; β -aa. β -aminoisobutyric acid; TGF- β . Transforming growth factor- β ; RANKL. Receptor activator of nuclear factor kappa-B ligand; INSL3. Insulin-like 3; CYP2R1. Cytochrome P450 family 2 subfamily R member 1; Th17. T helper 17; NOD1/2. Nucleotide-binding oligomerization domain 1/2; SCFAs. Short-chain fatty acids; TNO. Trimethylamine-N-oxide; Try. Tryptophan; KYN. Kynurenine; TLR5. Toll-like receptor 5; TH. Thyroid hormone; miR. MicroRNA

between bone and other organs through the utilization of animal models and clinical studies over the past few decades. However, there still exist numerous interorgan connections that pose challenges for further exploration due to discrepancies between model animals and humans as well as inadequate clinical models. Multiple diverse biotechnologies have emerged to address these issues and provide novel solutions for biology and clinical research.

The organ-on-a-chip technology replicates physiological microenvironments to mimic the intricate interactions between different tissues within the body[275]. It provides a dynamic platform for unraveling the complex network of biochemical signals and mechanical forces that govern bone-organ axes. By allowing manipulation and monitoring of these interactions within a controlled, physiologically relevant context, organ-on-a-chip technology elucidates the underlying mechanisms of bone-organ crosstalk in health and disease. Furthermore, advancements in organ-on-a-chip technology inherently rely on a profound understanding of bone-organ axes. The more we comprehend these axes, the more precise and effective our development of organ-on-a-chip models becomes.

The integration of two or more organs-on-a-chip in a dynamic fluid system enables the simulation of complex physiological and pathophysiological responses, as well as drug compound delivery, absorption, distribution, metabolism, and excretion (Fig. 5a). Bone-on-chip is a microarray-derived from induced pluripotent stem cells (iPSCs), primary cells, or

organoids[276,277] that can replicate the bone's physiological microenvironment and study bone-related diseases such as bone cancer, bone tumors, osteoporosis. It is used for research on bone disease models, drug screening, and pharmacokinetic/pharmacodynamic (PK/PD) analysis (Fig. 5b). For example, to simulate bone disease models, Chou *et al.*[278] designed a primary human vascularized bone marrow chip with top and bottom channels separated by a porous membrane. In the top channel, CD34⁺ cells and stromal cells derived from the bone marrow were cocultured within a 3D ECM gel. The bottom channel consisted of parallel channels lined with human vascular endothelial cells perfused with the culture medium. Vascularized bone marrow microarrays inoculated with CD34⁺ cells, BMSCs, and vascular endothelial cells could sustain various blood cell lineages for over one month in culture. They can replicate aspects of bone marrow injury, including granulocyte toxicity after exposure to clinically relevant chemotherapeutic agents or ionizing radiation and bone marrow recovery after drug-induced myelosuppression. They can also serve as an *in vitro* model of hematopoietic dysfunction.

In the field of drug screening research, McAleer *et al.*[279] developed a pump-free, reconfigurable, multiorganon-a-chip system that utilizes recirculating serum-free media to predict the preclinical efficacy of drug targeting, metabolic conversion, and off-target toxicity. This innovative system incorporates functional bio-microelectromechanical systems.




Fig. 5 The implications of bone-on-chips and assembloids in bone-organ axes.

a. Organ-on-a-chip system can simulate the physiological connections of organs in our bodies by simulating blood circulation through ordinary flow channels; b. The application of bone-on-chips in unraveling the mechanism of bone disease, drug screening, and PK/PD analysis; c. Assembloids integrated with bone and brain organoids. iPSCs. Induced pluripotent stem cell; PK/PD. Pharmacokinetic/pharmacodynamic; hPSCs. Human pluripotent stem cells

Primary human hepatocytes were co-cultured with two cancer-derived human bone marrow cell lines (Kasumi-1 myeloblasts and MEG-01 megakaryocytes) to examine the effects of antileukemia drugs. Their study revealed that diclofenac and imatinib exhibited cytostatic effects on myeloma proliferation. Imatinib did not show any adverse effects on liver viability; however, diclofenac reduced liver survival by 30%. For PK/PD analysis, Herland *et al.*[280] employed vascular endothelium-lined channel fluid-coupled bone marrow, liver, and kidney chips to establish a human model for drug absorption, metabolism, and excretion model of cisplatin (a cancer chemotherapy agent), enabling prediction of human PK parameters and PD responses. This multiorgan chip included an arteriovenous reservoir where cisplatin was administered to stimulate intravenous injection.

Assembloids are 3D aggregates of multiple organoids[281]. Their creation involves the controlled combination of different cell types, such as cell lines, primary cells, or iPSCs, to promote self-organization and the formation of tissue-like structures[282]. Assembloids provide researchers with a controlled environment to explore complex cellular behaviors, cell signaling pathways, and tissue development. Through *in vitro* integration of bone and other organoids (e.g., brain organoids), assembloids offer an unprecedented opportunity to delve into the cellular crosstalk and tissue-tissue interactions underlying bone-organ axes (Fig. 5c). Moreover, advancements in assembloid technology have been influenced by the exploration of bone-organ axes. Insights into the cellular and molecular mechanisms of bone-organ axes enable the development of more sophisticated and accurate assembloid models.

Both technologies are powerful tools for predicting and evaluating pathophysiological changes in bone-organ axes, providing a robust platform for developing and optimizing therapeutic strategies for bone-related and systemic diseases. By advancing our understanding of the etiology and progression of bone-organ axis diseases, these technologies lay the foundation for novel diagnostic and therapeutic approaches. In essence, the synergistic integration of organ-on-a-chip and assembloid technologies with the investigation of bone-organ axes holds immense potential to revolutionize our comprehension of bone-organ interactions. This interplay between research and technology establishes a robust groundwork for devising innovative strategies aimed at preventing, diagnosing, and treating both bone-associated and systemic diseases.

Conclusions

The bone-organ axes, characterized by bidirectional

communication *via* osteokines, EVs, hormones, and metabolites, are crucial in maintaining homeostasis and functionality across diverse organ systems. This review emphasizes the intricate crosstalk between bone and various organs, highlighting its potential implications for disease pathogenesis and treatment. However, systematically exploring these complex interrelationships remains an essential frontier in biomedical research. Many factors, mechanisms, and EVs involved in organ interactions still need to be investigated due to the limitations of existing experimental technologies and the inadequacy of the research methodologies. The underlying mechanisms governing the interactions between Alzheimer's disease and bone as well as the effects of lung cancer and bone injury are yet to be elucidated. Additionally, further investigation is needed to understand the mechanisms behind changes in bone mass observed in chronic liver disease.

To address these gaps in knowledge, we propose utilizing advanced techniques such as bone-on-chips, organoids, and assembloids that can simulate human organ-to-organ communication *in vitro*. These innovative approaches hold great promise for breakthroughs in scientific research. Furthermore, employing these new biotechniques can also facilitate investigations into factors or EVs that have been studied at cellular or animal levels with the aim of achieving significant advancements in disease treatment. However, it should be noted that there is ongoing controversy within the international research community regarding the pathology/physiology of EVs studied under laboratory conditions. Future investigations using advanced techniques will undoubtedly provide more insights into the intricate dynamics of bone-organ axes while paving the way for novel therapeutic strategies and an enhanced understanding of organismal physiology.

Abbreviations

ACTH: Adrenocorticotrophic hormone; AKI: Acute kidney injury; Akt: Protein kinase B; ALI: Acute lung injury; AP-1: Activator protein 1; BBB: Blood-brain barrier; BCAR1: Breast cancer anti-estrogen resistance 1; BMD: Bone mineral density; BMP-9: Bone morphogenetic protein-9; BMSC-EVs: Extracellular vesicles derived from bone marrow mesenchymal stem cells; BMSCs: Bone marrow mesenchymal stem cells; cAMP: Cyclic adenosine monophosphate; CART: Cocaine amphetamine-regulated transcript; CB: Cannabinoid; CCL2: C-C motif chemokine ligand 2; CCR2: C-C motif chemokine receptor 2; CF: Cystic fibrosis; CKD: Chronic kidney disease; CNS: Central nervous system; COPD: Chronic obstructive pulmonary disease; COVID-19: Chronic coronavirus disease 2019; CVDs: Cardiovascular diseases; CYP2R1: Cytochrome P450 family 2 subfamily R member 1; DA: Dopamine; DKK1: Dickkopf 1; ECM: Extracellular matrix; ENaC: Epithelial sodium channel; EPCs: Endothelial progenitor stem cells; EVs: Extracellular vesicles; FGF-21: Fibroblast growth factor-21; FSH: Follicle-stimulating hormone; GH: Growth hormone; Glu: Glutamate; GM: Gut microbiota; HIBD: Hypoxic-ischemic brain damage; HOD: Hepatic osteodystrophy;

IL-1: Interleukin-1; INSL3: Insulin-like 3; INSR: Insulin receptors; JNK: Janus kinase; KYN: Kynurenine; LCAT: Lecithin-cholesterol acyltransferase; LCN2: Lipocalin 2; LRP5: Low-density lipoprotein receptor-related protein 5; MAPK: Mitogen-activated protein kinase; MARCKS: Myristoylated alanine-rich protein kinase C substrate; MBD: Mineral and bone disease; MC4R: Melanocortin 4 receptor; MCAO: Middle cerebral artery occlusion; miR: MicroRNA; MM: Multiple myeloma; MSC: Mesenchymal stem cell; MSTN: Myostatin; NF- κ B: Nuclear factor kappa-B; NMU: Neuromedin U; NOD1/2: Nucleotide-binding oligomerization domain containing 1/2; NPY: Neuropeptide Y; NSCLC: Non-small cell lung cancer; OCN: Osteocalcin; OLT: Orthotopic liver transplantation; OP: Osteoporosis; OPG: Osteoprotegerin; OSX: Osterix; PGE2: Prostaglandin E2; PI3K: Phosphoinositide 3-kinase; PK/PD: Pharmacokinetic/pharmacodynamic; POMC: Proopiomelanocortin; PPARG: Peroxisome proliferator-activated receptor gamma; PTEN: Phosphatase and tensin homolog; PTH: Parathyroid hormone; RANKL: Receptor activator of nuclear factor kappa-B ligand; RUNX2: Runt-related transcription factor 2; RXFP2: Relaxin family peptide receptor 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SCFAs: Short-chain fatty acids; Semas: Semaphorins; SOST: Sclerostin; TBI: Traumatic brain injury; TH: Thyroid hormone; TLR4/5: Toll-like receptor 4/5; TNF- α : Tumor necrosis factor- α ; TNO: Trimethylamine-N-oxide; Treg: T regulatory; TRH: Thyrotropin-releasing hormone; Try: Tryptophan; TSH: Thyroid stimulating hormone; β -aa: β -aminoisobutyric acid; 5-HT: 5-hydroxytryptamine/serotonin.

Acknowledgements

Not applicable.

Authors' contributions

AFD drew the figures and wrote the manuscript. FXW and SCW helped modify the figures. LB revised the manuscript. JCS and YZZ conceived and supervised the study. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82230071, 82172098), the Integrated Project of Major Research Plan of National Natural Science Foundation of China (92249303), the Laboratory Animal Research Project of Shanghai Committee of Science and Technology (23141900600), the Shanghai Clinical Research Plan (SHDC2023CRT01), and the Young Elite Scientist Sponsorship Program by China Association for Science and Technology (YES20230049).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.

Author details

¹Institute of Translational Medicine, Organoid Research Center, Shanghai University, Shanghai 200444, China. ²National Center for Translational Medicine (Shanghai) SHU Branch, Shanghai University, Shanghai 200444, China. ³Department of Orthopedics, Shanghai Zhongye Hospital, Shanghai 200444, China. ⁴Department of Orthopaedics, the Third Hospital of Hebei Medical University, Orthopaedic Research Institution of Hebei Province, NHC Key Laboratory of Intelligent Orthopaedic Equipment, Shijiazhuang 050051, China. ⁵School of Medicine, Shanghai University, Shanghai 200444, China. ⁶Wenzhou Institute of Shanghai University, Wenzhou 325000, Zhejiang, China. ⁷Department of Orthopaedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

References

1. Zhou R, Guo Q, Xiao Y, Guo Q, Huang Y, Li C, *et al.* Endocrine role of bone in the regulation of energy metabolism. *Bone Res.* 2021;9(1):25.
2. Yuan W, Song C. Crosstalk between bone and other organs. *Med Rev.* 2022;2(4):331–48.
3. Schuh-Huerta SM, Pera RAR. Reproductive biology: bone returns the favour. *Nature.* 2011;472(7341):46–7.
4. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, *et al.* Osteocalcin regulates murine and human fertility through a pancreasbone-testis axis. *J Clin Invest.* 2013;123(6):2421–33.
5. Oury F. A crosstalk between bone and gonads. *Ann N Y Acad Sci.* 2012;1260:1–7.
6. Van Niel G, Carter DRF, Clayton A, Lambert DW, Raposo G, Vader P. Challenges and directions in studying cell-cell communication by extracellular vesicles. *Nat Rev Mol Cell Biol.* 2022;23(5):369–82.
7. Jiang J, Mei J, Ma Y, Jiang S, Zhang J, Yi S, *et al.* Tumor hijacks macrophages and microbiota through extracellular vesicles. *Exploration.* 2022;2(1):20210144.
8. Wang F, Gu Z, Yin Z, Zhang W, Bai L, Su J. Cell unit-inspired natural nano-based biomaterials as versatile building blocks for bone/cartilage regeneration. *J Nanobiotechnol.* 2023;21(1):293.
9. Xiong Y, Mi BB, Lin Z, Hu YQ, Yu L, Zha KK, *et al.* The role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity. *Mil Med Res.* 2022;9(1):65.
10. Jiang Y, Li J, Xue X, Yin Z, Xu K, Su J. Engineered extracellular vesicles for bone therapy. *Nano Today.* 2022;44:101487.
11. Lin L, Guo Z, He E, Long X, Wang D, Zhang Y, *et al.* SIRT2 regulates extracellular vesicle-mediated liver-bone communication. *Nat Metab.* 2023;5(5):821–41.
12. Rong X, Liu J, Yao X, Jiang T, Wang Y, Xie F. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/ β -catenin pathway. *Stem Cell Res Ther.* 2019;10(1):98.
13. Sun R, Liu W, Zhao Y, Chen H, Wang Z, Zhang Y, *et al.* Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related myocardial damage. *Cancer Cell Int.* 2021;21(1):311.
14. Qin W, Dallas SL. Exosomes and extracellular rna in muscle and bone aging and crosstalk. *Curr Osteoporos Rep.* 2019;17(6):548–59.
15. Liu X, Chen C, Jiang Y, Wan M, Jiao B, Liao X, *et al.* Brain-derived extracellular vesicles promote bone-fat imbalance in Alzheimer's disease. *Int J Bio Sci.* 2023;19(8):2409–27.

16. Soley L, Falank C, Reagan MR. MicroRNA transfer between bone marrow adipose and multiple myeloma cells. *Curr Osteoporos Rep.* 2017;15(3):162–70.
17. Kelly RR, Sidles SJ, LaRue AC. Effects of neurological disorders on bone health. *Front Psychol.* 2020;11:612366.
18. Zhang YW, Cao MM, Li YJ, Dai GC, Lu PP, Zhang M, et al. The regulative effect and repercussion of probiotics and prebiotics on osteoporosis: involvement of brain-gut-bone axis. *Crit Rev Food Sci Nutr.* 2023;63(25):7510–28.
19. Wan QQ, Qin WP, Ma YX, Shen MJ, Li J, Zhang ZB, et al. Crosstalk between bone and nerves within bone. *Adv Sci.* 2021; 8(7):2003390.
20. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. *Nature.* 2012;481(7381):314–20.
21. Wee NKY, Kulkarni RN, Horsnell H, Baldock PA. The brain in bone and fuel metabolism. *Bone.* 2016;82:56–63.
22. Horsnell H, Baldock PA. Osteoblastic actions of the neuropeptide Y system to regulate bone and energy homeostasis. *Curr Osteoporos Rep.* 2016;14(1):26–31.
23. Eleftheriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. *Nature.* 2005;434(7032):514–20.
24. Zaidi M. Skeletal remodeling in health and disease. *Nat Med.* 2007;13(7):791–801.
25. Ortuño MJ, Robinson ST, Subramanyam P, Paone R, Huang YY, Guo XE, et al. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. *Nat Med.* 2016;22(10):1170–9.
26. de Vernejoul MC, Collet C, Chabbi-Achengli Y. Serotonin: good or bad for bone. *Bonekey Rep.* 2012;1:120.
27. Ducey P, Karsenty G. The two faces of serotonin in bone biology. *J Cell Biol.* 2010;191(1):7–13.
28. Sheu Yh, Lanteigne A, Stürmer T, Pate V, Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders. *Inj Prev.* 2015;21(6):397–403.
29. Perälä N, Sariola H, Immonen T. More than nervous: the emerging roles of plexins. *Differentiation.* 2012;83(1):77–91.
30. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. *Nature.* 2012;485(7396):69–74.
31. Dacquin R, Domenget C, Kumanogoh A, Kikutani H, Jurdic P, Machuca-Gayet I. Control of bone resorption by semaphorin 4D is dependent on ovarian function. *PLoS One.* 2011;6(10):e26627.
32. Böhm M, Grässel S. Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. *Endocr Rev.* 2012;33(4):623–51.
33. Grässel S, Muschter D. Do neuroendocrine peptides and their receptors qualify as novel therapeutic targets in osteoarthritis?. *Int J Mol Sci.* 2018;19(2):367.
34. Farman HH, Windahl SH, Westberg L, Isaksson H, Egecioglu E, Schele E, et al. Female mice lacking estrogen receptor- α in hypothalamic proopiomelanocortin (POMC) neurons display enhanced estrogenic response on cortical bone mass. *Endocrinology.* 2016;157(8):3242–52.
35. Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, et al. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. *J Biol Chem.* 2000;275(42): 32452–9.
36. Martinez VG, O'Driscoll L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. *Clin Chem.* 2015;61(3):471–82.
37. Wang CX, Ge XY, Wang MY, Ma T, Zhang Y, Lin Y. Dopamine D1 receptor-mediated activation of the ERK signaling pathway is involved in the osteogenic differentiation of bone mesenchymal stem cells. *Stem Cell Res Ther.* 2020;11(1):13.
38. Cheong PU, Ma T, Zheng Y, Ge XY, Zhang Y, Lin Y. Dopamine receptor expression on primary osteoblasts and bone marrow mesenchymal stem cells of rats. *Int J Clin Exp Med.* 2018;11(3): 1765–71.
39. Lee DJ, Tseng HC, Wong SW, Wang Z, Deng M, Ko CC. Dopaminergic effects on *in vitro* osteogenesis. *Bone Res.* 2015; 3:15020.
40. Hanami K, Nakano K, Saito K, Okada Y, Yamaoka K, Kubo S, et al. Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. *Bone.* 2013;56(1):1–8.
41. Zhou T, Yang Y, Chen Q, Xie L. Glutamine metabolism is essential for stemness of bone marrow mesenchymal stem cells and bone homeostasis. *Stem Cells Int.* 2019;2019:8928934.
42. Vlashi R, Zhang X, Wu M, Chen G. Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders. *Genes Dis.* 2022;10(4):1291–317.
43. Merle B, Itzstein C, Delmas PD, Chenu C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. *J Cell Biochem.* 2003;90(2):424–36.
44. Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S, et al. Secretion of L-glutamate from osteoclasts through transcytosis. *EMBO J.* 2006;25(18):4175–86.
45. Miladinovic T, Nashed MG, Singh G. Overview of glutamatergic dysregulation in central pathologies. *Biomolecules.* 2015;5(4): 3112–41.
46. Raphael-Mizrahi B, Gabet Y. The cannabinoids effect on bone formation and bone healing. *Curr Osteoporos Rep.* 2020;18(5): 433–8.
47. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. *Proc Natl Acad Sci U S A.* 2006;103(3):696–701.
48. Deis S, Srivastava RK, Ruiz de Azua I, Bindila L, Baraghithy S, Lutz B, et al. Age-related regulation of bone formation by the sympathetic cannabinoid CB1 receptor. *Bone.* 2018;108:34–42.
49. Karsak M, Malkin I, Toliat MR, Kubisch C, Nürnberg P, Zimmer A, et al. The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample. *Hum Genet.* 2009;126(5):629–36.
50. Jørgensen AP, Bollerslev J. Bone: growth hormone replacement-implications for bone health. *Nat Rev Endocrinol.* 2012;8(6):325–6.
51. Mills EG, Yang L, Nielsen MF, Kassem M, Dhillon WS, Comninos AN. The relationship between bone and reproductive hormones beyond estrogens and androgens. *Endocr Rev.* 2021;42(6):691–719.
52. Coss D. Commentary on the recent FSH collection: known knowns and known unknowns. *Endocrinology.* 2020;161(1):bqz035.
53. Mazziotti G, Frara S, Giustina A. Pituitary diseases and bone. *Endocr Rev.* 2018;39(4):440–88.
54. Baliram R, Latif R, Zaidi M, Davies TF. Expanding the role of thyroid-stimulating hormone in skeletal physiology. *Front Endocrinol.* 2017;8:252.
55. Kim SM, Ryu V, Miyashita S, Korkmaz F, Lizneva D, Gera S, et al.

- Thyrotropin, hyperthyroidism, and bone mass. *J Clin Endocrinol Metab.* 2021;106(12):e4809–21.
56. Chamouni A, Schreiweis C, Oury F. Bone, brain & beyond. *Rev Endocr Metab Dis.* 2015;16(2):99–113.
 57. Isales CM, Zaidi M, Blair HC. ACTH is a novel regulator of bone mass. *Ann N Y Acad Sci.* 2010;1192:110–6.
 58. Weinstein RS. Glucocorticoid-induced osteonecrosis. *Endocrine.* 2012;41(2):183–90.
 59. Foertsch S, Haffner-Luntzer M, Kroner J, Gross F, Kaiser K, Erber M, et al. Chronic psychosocial stress disturbs long-bone growth in adolescent mice. *Dis Model Mech.* 2017;10(12):1399–409.
 60. Diaz-Franco MC, Franco-Diaz de Leon R, Villafan-Bernal JR. Osteocalcin-GPRC6A: an update of its clinical and biological multi-organic interactions (review). *Mol Med Rep.* 2019;19(1):15–22.
 61. Obri A, Khimian L, Karsenty G, Oury F. Osteocalcin in the brain: from embryonic development to age-related decline in cognition. *Nat Rev Endocrinol.* 2018;14(3):174–82.
 62. Mera P, Ferron M, Mosialou I. Regulation of energy metabolism by bone-derived hormones. *Cold Spring Harb Perspect Med.* 2018;8(6):a031666.
 63. Mosialou I, Shikhel S, Liu JM, Maurizi A, Luo N, He Z, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. *Nature.* 2017;543(7645):385–90.
 64. Houweling P, Kulkarni RN, Baldock PA. Neuronal control of bone and muscle. *Bone.* 2015;80:95–100.
 65. Koide M, Kobayashi Y. Regulatory mechanisms of sclerostin expression during bone remodeling. *J Bone Miner Metab.* 2019;37(1):9–17.
 66. Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. *Int J Womens Health.* 2015;7:565–80.
 67. Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. *Bone.* 2017;96:45–50.
 68. Yuan J, Meloni BP, Shi T, Bonser A, Papadimitriou JM, Mastaglia FL, et al. The potential influence of bone-derived modulators on the progression of Alzheimer's disease. *J Alzheimers Dis.* 2019;69(1):59–70.
 69. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang Y-W, Rosol TJ, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. *Blood.* 2009;113(3):517–25.
 70. Huang Y, Liu L, Liu A. Dickkopf-1: current knowledge and related diseases. *Life Sci.* 2018;209:249–54.
 71. Okamoto M, Inoue K, Iwamura H, Terashima K, Soya H, Asashima M, et al. Reduction in paracrine Wnt3 factors during aging causes impaired adult neurogenesis. *FASEB J.* 2011;25(10):3570–82.
 72. Mazziotti G, Lania AG, Canalis E. Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis. *Nat Rev Endocrinol.* 2022;18(6):353–65.
 73. Tahimic CG, Wang Y, Bikle DD. Anabolic effects of IGF-1 signaling on the skeleton. *Front Endocrinol.* 2013;4:6.
 74. Al-Massadi O, Parini P, Fernø J, Luquet S, Quiñones M. Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system. *Rev Endocr Metab Disord.* 2022;23(5):919–30.
 75. Xiong Y, Zhong W, Mi B. The mechanism of bone healing after traumatic brain injury. *Brain-X.* 2023;1(3):e31.
 76. Xia W, Xie J, Cai Z, Liu X, Wen J, Cui ZK, et al. Damaged brain accelerates bone healing by releasing small extracellular vesicles that target osteoprogenitors. *Nat Commun.* 2021;12(1):6043.
 77. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med.* 2013;19(2):179–92.
 78. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med.* 2017;377(15):1417–27.
 79. Jia L, Piña-Crespo J, Li Y. Restoring Wnt/ β -catenin signaling is a promising therapeutic strategy for Alzheimer's disease. *Mol Brain.* 2019;12(1):104.
 80. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. *Bone.* 2006;39(4):754–66.
 81. Ren C, Gu X, Li H, Lei S, Wang Z, Wang J, et al. The role of DKK1 in Alzheimer's disease: a potential intervention point of brain damage prevention?. *Pharmacol Res.* 2019;144:331–5.
 82. Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid β -mediated synaptic loss. *J Neurosci.* 2012;32(10):3492–8.
 83. Li J, Zhang D, Guo S, Zhao C, Wang L, Ma S, et al. Dual-enzymatically cross-linked gelatin hydrogel promotes neural differentiation and neurotrophin secretion of bone marrow-derived mesenchymal stem cells for treatment of moderate traumatic brain injury. *Int J Biol Macromol.* 2021;187:200–13.
 84. Li Q, Tan Y, Chen S, Xiao X, Zhang M, Wu Q, et al. Irisin alleviates LPS-induced liver injury and inflammation through inhibition of NLRP3 inflammasome and NF- κ B signaling. *J Recept Sig Transd.* 2021;41(3):294–303.
 85. Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in neurogenesis and nervous system repair. *Neurochem Int.* 2011;59(3):347–56.
 86. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. *Stem Cells.* 2017;35(4):851–8.
 87. Liu X, Zhang M, Liu H, Zhu R, He H, Zhou Y, et al. Bone marrow mesenchymal stem cell-derived exosomes attenuate cerebral ischemia-reperfusion injury-induced neuroinflammation and pyroptosis by modulating microglia M1/M2 phenotypes. *Exp Neurol.* 2021;341:113700.
 88. Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. *Genom Proteom Bioinf.* 2015;13(1):17–24.
 89. Tian J, Yao H, Liu Y, Wang X, Wu J, Wang J, et al. Extracellular vesicles from bone marrow stromal cells reduce the impact of stroke on glial cell activation and blood brain-barrier permeability via a putative miR-124/PRX1 signalling pathway. *Eur J Neurosci.* 2022;56(2):3786–805.
 90. Min W, Wu Y, Fang Y, Hong B, Dai D, Zhou Y, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-124-3p attenuates hypoxic-ischemic brain damage through depressing tumor necrosis factor receptor associated factor 6 in newborn rats. *Bioengineered.* 2022;13(2):3194–206.
 91. Deng Y, Chen D, Gao F, Lv H, Zhang G, Sun X, et al. Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2. *J Biol Eng.* 2019;13:71.
 92. Dong C, Chen M, Cai B, Zhang C, Xiao G, Luo W. Mesenchymal stem cell-derived exosomes improved cerebral infarction via transferring miR-23a-3p to activate microglia. *Neuromol Med.* 2022;24(3):290–8.
 93. Singleton Q, Vaibhav K, Braun M, Patel C, Khayrullin A, Mendhe B,

- et al.* Bone marrow derived extracellular vesicles activate osteoclast differentiation in traumatic brain injury induced bone loss. *Cells*. 2019;8(1):63.
94. Shi X, Zhong X, Deng L, Wu X, Zhang P, Zhang X, *et al.* Mesenchymal stem cell-derived extracellular vesicle-enclosed microRNA-93 prevents hypoxic-ischemic brain damage in rats. *Neuroscience*. 2022;500:12–25.
95. Yang H, Chen J. Bone marrow mesenchymal stem cell-derived exosomes carrying long noncoding RNA ZFAS1 alleviate oxidative stress and inflammation in ischemic stroke by inhibiting microRNA-15a-5p. *Metab Brain Dis*. 2022;37(7):2545–57.
96. Shen M, Zheng R, Kan X. Neuroprotection of bone marrow-derived mesenchymal stem cell-derived extracellular vesicle-enclosed mir-410 correlates with HDAC4 knockdown in hypoxic-ischemic brain damage. *Neurochem Res*. 2022;47(10):3150–66.
97. Xiong L, Sun L, Zhang Y, Peng J, Yan J, Liu X. Exosomes from bone marrow mesenchymal stem cells can alleviate early brain injury after subarachnoid hemorrhage through miRNA129-5p-HMGB1 pathway. *Stem Cells Dev*. 2020;29(4):212–21.
98. Cui GH, Wu J, Mou FF, Xie WH, Wang FB, Wang QL, *et al.* Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice. *FASEB J*. 2018;32(2):654–68.
99. Sha S, Shen X, Cao Y, Qu L. Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer's disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/ β -catenin pathway. *Aging*. 2021;13(11):15285–306.
100. Engblom C, Pflirschke C, Zilionis R, Martins JD, Bos SA, Courties G, *et al.* Osteoblasts remotely supply lung tumors with cancer-promoting Siglec^F^{high} neutrophils. *Science*. 2017;358(6367):15.
101. Celli BR, Anderson JA, Cowans NJ, Crim C, Hartley BF, Martinez FJ, *et al.* Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review. *Am J Respir Crit Care Med*. 2021;203(6):689–98.
102. Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis. *Adv Med Sci*. 2013;58(2):338–43.
103. Rattanapisit K, Yusakul G, Shanmugaraj B, Kittitruji K, Suwatsrisakul P, Prompetchara E, *et al.* Plant-produced recombinant SARS-CoV-2 receptor-binding domain; an economical, scalable biomaterial source for COVID-19 diagnosis. *Biomater Transl*. 2021;2(1):43–9.
104. Hu Q, Zhang S, Yang Y, Yao JQ, Tang WF, Lyon CJ, *et al.* Extracellular vesicles in the pathogenesis and treatment of acute lung injury. *Mil Med Res*. 2022;9(1):61.
105. Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. *Lancet*. 2012;379(9823):1341–51.
106. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of "overspill" of inflammatory mediators from the lungs? Review of the evidence. *Thorax*. 2010;65(10):930–6.
107. Hoepers ATD, Menezes MM, Frode TS. Systematic review of anaemia and inflammatory markers in chronic obstructive pulmonary disease. *Clin Exp Pharmacol Physiol*. 2015;42(3):231–9.
108. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease reply. *N Engl J Med*. 2015;372(16):1574–5.
109. Marquette M, Haworth CS. Bone health and disease in cystic fibrosis. *Paediatr Respir Rev*. 2016;20(Suppl):2–5.
110. Rossini M, Del Marco A, Dal Santo F, Gatti D, Braggion C, James G, *et al.* Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. *Bone*. 2004;35(3):771–6.
111. Qiao W, Lau HE, Xie HZ, Poon VKM, Chan CCS, Chu H, *et al.* SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. *Nat Commun*. 2022;13(1):16.
112. Taverna S, Pucci M, Giallombardo M, Di Bella MA, Santarpia M, Reclusa P, *et al.* Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway. *Sci Rep*. 2017;7(1):3170.
113. Xu Z, Liu X, Wang H, Li J, Dai L, Li J, *et al.* Lung adenocarcinoma cell-derived exosomal miR-21 facilitates osteoclastogenesis. *Gene*. 2018;666:116–22.
114. Hua Y, Han A, Yu T, Hou Y, Ding Y, Nie H. Small extracellular vesicles containing miR-34c derived from bone marrow mesenchymal stem cells regulates epithelial sodium channel via targeting MARCKs. *Int J Mol Sci*. 2022;23(9):5196.
115. Liu J, Feng Y, Zeng X, He M, Gong Y, Liu Y. Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis. *J Cell Mol Med*. 2020;25(4):1911–26.
116. Liu X, Jiang F, Wang Z, Tang L, Zou B, Xu P, *et al.* Hypoxic bone marrow mesenchymal cell-extracellular vesicles containing miR-328-3p promote lung cancer progression via the NF2-mediated Hippo axis. *J Cell Mol Med*. 2021;25(1):96–109.
117. Wang J, Huang R, Xu Q, Zheng G, Qiu G, Ge M, *et al.* Mesenchymal stem cell-derived extracellular vesicles alleviate acute lung injury via transfer of miR-27a-3p. *Crit Care Med*. 2020;48(7):e599–610.
118. Liang Y, Zhang D, Li L, Xin T, Zhao Y, Ma R, *et al.* Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2. *Stem Cell Res Ther*. 2020;11(1):87.
119. Jin X, Li Y, Li J, Cheng L, Yao Y, Shen H, *et al.* Acute bone damage through liver-bone axis induced by thioacetamide in rats. *BMC Pharmacol Toxicol*. 2022;23(1):29.
120. Norris CA, He M, Kang LI, Ding MQ, Radder JE, Haynes MM, *et al.* Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. *PLoS One*. 2019;14(10):3.
121. Shimada M, Matsumata T, Taketomi A, Shirabe K, Yamamoto K, Takenaka K, *et al.* The role of interleukin-6, interleukin-16, tumor necrosis factor alpha and endotoxin in hepatic resection. *Hepato-gastroenterol*. 1995;42(5):691–7.
122. Handzlik-Orlik G, Holecki M, Wilczynski K, Dulawa J. Osteoporosis in liver disease: pathogenesis and management. *Ther Adv Endocrinol*. 2016;7(3):128–35.
123. Guarino M, Loperto I, Camera S, Cossiga V, Di Somma C, Colao A, *et al.* Osteoporosis across chronic liver disease. *Osteoporosis Int*. 2016;27(6):1967–77.
124. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. *Int J Clin Exp Med*. 2015;8(10):17221–34.
125. Wijnia JW, Wielders JPM, Lips P, van de Wiel A, Mulder CL, Nieuwenhuis KGA. Is vitamin D deficiency a confounder in alcoholic skeletal muscle myopathy?. *Alcohol Clin Exp Res*. 2013;37:E209–15.
126. Goubraim R, Kabbaj N, Salihoun M, Chaoui Z, Nya MH, Amrani N. Metabolic bone disease in viral cirrhosis: a prospective study. *Hepatology*. 2013;2013: 276563.
127. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, deOsaba MJM, *et al.* Osteoporosis and bone mineral metabolism disorders

- in cirrhotic patients referred for orthotopic liver transplantation. *Calcified Tissue Int.* 1997;60(2):148–54.
128. Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, Vázquez-Carrera M. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. *Trends Pharmacol Sci.* 2020;41(3):199–208.
129. Wang X, Wei W, Krzeszinski JY, Wang Y, Wan Y. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. *Cell Metab.* 2015;22(5):811–24.
130. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ . *Proc Natl Acad Sci U S A.* 2012;109(8):3143–8.
131. Um JH, Park SY, Hur JH, Lee HY, Jeong KH, Cho Y, et al. Bone morphogenic protein 9 is a novel thermogenic hepatokine secreted in response to cold exposure. *Metabolism.* 2022;129:155139.
132. Zhou YM, Yang YY, Jing YX, Yuan TJ, Sun LH, Tao B, et al. BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling. *J Bone Miner Res Plus.* 2020;35(5):978–93.
133. Guanabens N, Ruiz-Gaspa S, Gifre L, Miquel R, Peris P, Monegal A, et al. Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis. *J Bone Miner Res.* 2016;31(9):1725–33.
134. Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. *Bone.* 2017;96:29–37.
135. Reid IR. Targeting sclerostin in postmenopausal osteoporosis: focus on romosozumab and blosozumab. *BioDrugs.* 2017;31(4):289–97.
136. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporosis. *Int J Endocrinol.* 2014;2014:235060.
137. Kobayashi Y, Uehara S, Koide M, Takahashi N. The regulation of osteoclast differentiation by Wnt signals. *Bonekey Rep.* 2015;4:713.
138. Guerra-Menendez L, Sadaba MC, Puche JE, Lavandera JL, de Castro LF, de Gortazar AR, et al. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. *J Transl Med.* 2013;11:12.
139. Lu K, Shi TS, Shen SY, Shi Y, Gao HL, Wu J, et al. Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. *Cell Metab.* 2022;34(3):441–57.e7.
140. Wei H, Wang J, Xu Z, Li W, Wu X, Zhuo C, et al. Hepatoma cell-derived extracellular vesicles promote liver cancer metastasis by inducing the differentiation of bone marrow stem cells through microRNA-181d-5p and the FAK/SRC pathway. *Front Cell Dev Biol.* 2021;9:607001.
141. Han S, Xue L, Wei Y, Yong T, Jia W, Qi Y, et al. Bone lesion-derived extracellular vesicles fuel prometastatic cascades in hepatocellular carcinoma by transferring ALKBH5-targeting miR-3190-5p. *Adv Sci.* 2023;10(17):e2207080.
142. Zhou M, Hui J, Gao L, Liang J, Wang C, Xu J. Extracellular vesicles from bone marrow mesenchymal stem cells alleviate acute rejection injury after liver transplantation by carrying miR-22-3p and inducing M2 polarization of Kupffer cells. *J Gene Med.* 2023;25(7):e3497.
143. Haga H, Yan IK, Takahashi K, Matsuda A, Patel T. Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice. *Stem Cells Transl Med.* 2017;6(4):1262–72.
144. Xuan J, Xu H, Li H, Chen D, Qiu Y, Chen X, et al. Extracellular vesicles from miR-148a-5p-enriched bone marrow mesenchymal stem cells relieve hepatic fibrosis by targeting SMAD4. *Mol Biotechnol.* 2022;64(5):535–45.
145. Zhang J, Gao J, Li X, Lin D, Li Z, Wang J, et al. Bone marrow mesenchymal stem cell-derived small extracellular vesicles promote liver regeneration via miR-20a-5p/PTEN. *Front Pharmacol.* 2023;14:1168545.
146. Hristov M, Erl W, Weber PC. Endothelial progenitor cells-isolation and characterization. *Trends Cardiovas Med.* 2003;13(5):201–6.
147. Kucia M, Dawn B, Hunt G, Guo YR, Wysoczynski M, Majka M, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. *Circ Res.* 2004;95(12):1191–9.
148. Rohde D, Vandoorne K, Lee IH, Grune J, Zhang S, McAlpine CS, et al. Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. *Nat Cardiovasc Res.* 2022;1(1):28–44.
149. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med.* 2005;353(10):999–1007.
150. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?. *J Mol Med.* 2004;82(10):671–7.
151. Yu B, Kim HW, Gong M, Wang J, Millard RW, Wang Y, et al. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. *Int J Cardiol.* 2015;182:349–60.
152. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting *Mecp2* via miR-22. *PLoS One.* 2014;9(2):e88685.
153. Cheng M, Yang J, Zhao X, Zhang E, Zeng Q, Yu Y, et al. Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. *Nat Commun.* 2019;10(1):959.
154. Borzych D, Rees L, Ha IS, Chua A, Valles PG, Lipka M, et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. *Kidney Int.* 2010;78(12):1295–304.
155. Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, et al. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. *Nephrol Dial Transplant.* 2013;28(1):153–61.
156. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. *Clin J Am Soc Nephrol.* 2014;9(2):344–53.
157. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int.* 2007;71(1):31–8.
158. Massy ZA, Drueke TB. A new player in the kidney-bone axis: regulation of fibroblast growth factor-23 by renal glycerol-3-phosphate. *Kidney Int.* 2020;98(5):1074–6.
159. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. *Kidney Int.* 2003;64(6):2272–9.
160. Carrillo-López N, Panizo S, Alonso-Montes C, Román-García P, Rodríguez I, Martínez-Salgado C, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. *Kidney Int.*

- 2016;90(1):77–89.
161. Hruska KA, Seifert M, Sugatani T. Pathophysiology of the chronic kidney disease-mineral bone disorder. *Curr Opin Nephrol Hy.* 2015;24(4):303–9.
162. Nordholm A, Mace ML, Gravesen E, Hofman-Bang J, Morevati M, Olgaard K, et al. Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. *Am J Physiol Renal Physiol.* 2018;314(5):F753–62.
163. Williams MJ, Sugatani T, Agapova OA, Fang Y, Gaut JP, Faugere MC, et al. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. *Kidney Int.* 2018;93(1):147–58.
164. Lodberg A. Principles of the activin receptor signaling pathway and its inhibition. *Cytokine Growth Factor Rev.* 2021;60:1–17.
165. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res.* 2004;19(3):429–35.
166. Saito H, Kusano K, Kinoshita M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na⁺-dependent phosphate co-transport activity and 1 α , 25-dihydroxyvitamin D3 production. *J Biol Chem.* 2003;278(4):2206–11.
167. Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. *Nat Med.* 2017;23(1):100–6.
168. Shen B, Liu J, Zhang F, Wang Y, Qin Y, Zhou Z, et al. CCR2 positive exosome released by mesenchymal stem cells suppresses macrophage functions and alleviates ischemia/reperfusion-induced renal injury. *Stem Cells Int.* 2016;2016:1240301.
169. Cao H, Cheng Y, Gao H, Zhuang J, Zhang W, Bian Q, et al. *In vivo* tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. *ACS Nano.* 2020;14(4):4014–26.
170. Tapparo M, Bruno S, Collino F, Togliatto G, Deregibus MC, Provero P, et al. Renal regenerative potential of extracellular vesicles derived from miRNA-engineered mesenchymal stromal cells. *Int J Mol Sci.* 2019;20(10):2381.
171. Bruno S, Tapparo M, Collino F, Chiabotto G, Deregibus MC, Soares Lindoso R, et al. Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells. *Tissue Eng Part A.* 2017;23(21–22):1262–73.
172. Wang B, Yao K, Huuskos BM, Shen HH, Zhuang J, Godson C, et al. Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis. *Mol Ther.* 2016;24(7):1290–301.
173. Gries KJ, Zysik VS, Jobe TK, Griffin N, Leeds BP, Lowery JW. Musclederived factors influencing bone metabolism. *Semin Cell Dev Biol.* 2022;123:57–63.
174. Qin Y, Peng Y, Zhao W, Pan J, Ksiezak-Reding H, Cardozo C, et al. Myostatin inhibits osteoblastic differentiation by suppressing osteocytederived exosomal microRNA-218: a novel mechanism in muscle-bone communication. *J Biol Chem.* 2017;292(26):11021–33.
175. Colaianni G, Mongelli T, Colucci S, Cinti S, Grano M. Crosstalk between muscle and bone via the muscle-myokine irisin. *Curr Osteoporos Rep.* 2016;14(4):132–7.
176. Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. The myokine irisin increases cortical bone mass. *Proc Natl Acad Sci U S A.* 2015;112(39):12157–62.
177. Kitase Y, Vallejo JA, Gutheil W, Vemula H, Jähn K, Yi J, et al. β -aminoisobutyric acid, I-BAIBA, is a muscle-derived osteocyte survival factor. *Cell Rep.* 2018;22(6):1531–44.
178. Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, Barton ER. Role of IGF-I signaling in muscle bone interactions. *Bone.* 2015;80:79–88.
179. Coffin JD, Homer-Bouthiette C, Hurley MM. Fibroblast growth factor 2 and its receptors in bone biology and disease. *J Endocr Soc.* 2018;2(7):657–71.
180. Xu Q, Cui Y, Luan J, Zhou X, Li H, Han J. Exosomes from C2C12 myoblasts enhance osteogenic differentiation of MC3T3-E1 preosteoblasts by delivering miR-27a-3p. *Biochem Biophys Res Commun.* 2018;498(1):32–7.
181. Huang Z, Chen X, Yu B, He J, Chen D. MicroRNA-27a promotes myoblast proliferation by targeting myostatin. *Biochem Biophys Res Commun.* 2012;423(2):265–9.
182. Chen X, Huang Z, Chen D, Yang T, Liu G. Role of microRNA-27a in myoblast differentiation. *Cell Biol Int.* 2014;38(2):266–71.
183. Wang B, Zhang C, Zhang A, Cai H, Price SR, Wang XH. MicroRNA-23a and microRNA-27a mimic exercise by ameliorating ckd-induced muscle atrophy. *J Am Soc Nephrol.* 2017;28(9):2631–40.
184. Fulzele S, Mendhe B, Khayrullin A, Johnson M, Kaiser H, Liu Y, et al. Muscle-derived miR-34a increases with age in circulating extracellular vesicles and induces senescence of bone marrow stem cells. *Aging.* 2019;11(6):1791–803.
185. Mohamed JS, Wilson JC, Myers MJ, Sisson KJ, Alway SE. Dysregulation of SIRT-1 in aging mice increases skeletal muscle fatigue by a PARP-1-dependent mechanism. *Aging.* 2014;6(10):820–34.
186. Kukreti H, Amuthavalli K. MicroRNA-34a causes ceramide accumulation and effects insulin signaling pathway by targeting ceramide kinase (CERK) in aging skeletal muscle. *J Cell Biochem.* 2020;121(5–6):3070–89.
187. Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galán-Díez M, et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. *Cell Metab.* 2016;23(6):1078–92.
188. Chowdhury S, Schulz L, Palmisano B, Singh P, Berger JM, Yadav VK, et al. Muscle-derived interleukin 6 increases exercise capacity by signaling in osteoblasts. *J Clin Invest.* 2020;130(6):2888–902.
189. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF- β mediates muscle weakness associated with bone metastases in mice. *Nat Med.* 2015;21(11):1262–71.
190. Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, et al. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/ β -catenin pathway. *JBMR Plus.* 2017;1(2):86–100.
191. Carpenter KA, Ross RD. Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing hyp mice. *J Bone Miner Res.* 2020;35(3):596–607.
192. Sebastian A, Loots GG. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models. *Metabolism.* 2018;80:38–47.
193. Robling AG, Niziolek PJ, Baldrige LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone *in vivo* reduces osteocyte expression of Sost/sclerostin. *J Biol Chem.* 2008;283(9):5866–75.
194. Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Boussein ML, Sibonga JD, et al. Serum sclerostin increases in healthy adult men during bed rest. *J Clin Endocrinol Metab.* 2012;97(9):E1736–40.
195. Ho ATV, Palla AR, Blake MR, Yucel ND, Wang YX, Magnusson KEG,

- et al.* Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength. *Proc Natl Acad Sci U S A.* 2017;114(26):6675–84.
196. Kamel MA, Picconi JL, Lara-Castillo N, Johnson ML. Activation of β -catenin signaling in MLO-Y4 osteocytic cells *versus* 2T3 osteoblastic cells by fluid flow shear stress and PGE2: implications for the study of mechanosensation in bone. *Bone.* 2010;47(5):872–81.
197. Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, *et al.* Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts *via* EP4 receptor activation. *Cell Cycle.* 2015;14(10):1507–16.
198. Palla AR, Ravichandran M, Wang YX, Alexandrova L, Yang AV, Kraft P, *et al.* Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength. *Science.* 2021;371(6528):eabc8059.
199. Mendias CL, Gumucio JP, Davis ME, Bromley CW, Davis CS, Brooks SV. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. *Muscle Nerve.* 2012;45(1):55–9.
200. Li G, Zhang L, Wang D, Aiqudsy L, Jiang JX, Xu H, *et al.* Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. *J Cell Biochem.* 2019;120(9):14262–73.
201. McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P, *et al.* Osteoclasts recycle *via* osteomorphs during RANKL-stimulated bone resorption. *Cell.* 2021;184(5):1330–47.e13.
202. Dufresne SS, Dumont NA, Boulanger-Piette A, Fajardo VA, Gamu D, Kake-Guena SA, *et al.* Muscle RANK is a key regulator of Ca^{2+} storage, SERCA activity, and function of fast-twitch skeletal muscles. *Am J Physiol Cell Physiol.* 2016;310(8):C663–72.
203. Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, *et al.* An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. *Hum Mol Genet.* 2019;28(18):3101–12.
204. Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. *J Clin Invest.* 2019;129(8):3214–23.
205. Fintini D, Cianfarani S, Cofini M, Andreoletti A, Ubertini GM, Cappa M, *et al.* The bones of children with obesity. *Front Endocrinol.* 2020;11:200.
206. Ducey P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, *et al.* Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell.* 2000;100(2):197–207.
207. Karczewska-Kupczewska M, Straczkowski M, Adamska A, Nikołaajuk A, Otziomek E, Górska M, *et al.* Insulin sensitivity, metabolic flexibility, and serum adiponectin concentration in women with anorexia nervosa. *Metabolism.* 2010;59(4):473–7.
208. Ecklund K, Vajapeyam S, Feldman HA, Buzney CD, Mulkern RV, Kleinman PK, *et al.* Bone marrow changes in adolescent girls with anorexia nervosa. *J Bone Miner Res.* 2010;25(2):298–304.
209. Tencerova M, Ferencakova M, Kassem M. Bone marrow adipose tissue: role in bone remodeling and energy metabolism. *Best Pract Res Clin En.* 2021;35(4):101545.
210. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, *et al.* Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature.* 2002;418(6893):41–9.
211. Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. *J Intern Med.* 2012;272(4):317–29.
212. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. *J Biol Chem.* 2007;282(19):14515–24.
213. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, *et al.* Modulation of osteoclastogenesis by fatty acids. *Endocrinol.* 2008;149(11):5688–95.
214. Zhang Y, Zhang C, Wang J, Liu H, Wang M. Bone-adipose tissue crosstalk: role of adipose tissue derived extracellular vesicles in bone diseases. *J Cell Physiol.* 2021;236(11):7874–86.
215. Jones CI, Zabolotskaya MV, King AJ, Stewart HJS, Horne GA, Chevassut TJ, *et al.* Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. *Br J Cancer.* 2012;107(12):1987–96.
216. Chen S, Tang Y, Liu Y, Zhang P, Lv L, Zhang X, *et al.* Exosomes derived from miR-375-overexpressing human adipose mesenchymal stem cells promote bone regeneration. *Cell Prolif.* 2019;52(5):e12669.
217. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *J Clin Invest.* 2011;121(6):2094–101.
218. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. *Trends Endocrinol Metab.* 2012;23(11):576–81.
219. Robinson LJ, Yaroslavskiy BB, Griswold RD, Zadorozny EV, Guo L, Tourkova IL, *et al.* Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6. *Exp Cell Res.* 2009;315(7):1287–301.
220. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, *et al.* Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. *Cell.* 2001;104(5):719–30.
221. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, *et al.* Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. *J Clin Invest.* 2003;111(11):1651–64.
222. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. *Endocr Rev.* 2004;25(3):389–425.
223. Marcus R, Leary D, Schneider DL, Shane E, Favus M, Quigley CA. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. *J Clin Endocrinol Metab.* 2000;85(3):1032–7.
224. Ferlin A, Perilli L, Giansello L, Tagliavaloro G, Foresta C. Profiling insulin like factor 3 (INSL3) signaling in human osteoblasts. *PLoS One.* 2011;6(12):e29733.
225. Ferlin A, Selice R, Carraro U, Foresta C. Testicular function and bone metabolism-beyond testosterone. *Nat Rev Endocrinol.* 2013;9(9):548–54.
226. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, *et al.* Endocrine regulation of male fertility by the skeleton. *Cell.* 2011;144(5):796–809.
227. Li LS, Rao ST, Cheng YZ, Zhuo XY, Deng CH, Xu NN, *et al.* Microbial osteoporosis: The interplay between the gut microbiota and bones *via* host metabolism and immunity. *Microbiol Open.* 2019;8(8):15.
228. Yan J, Charles JF. Gut microbiome and bone: to build, destroy, or both?. *Curr Osteoporos Rep.* 2017;15(4):376–84.
229. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, *et al.* Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. *J Exp Med.* 2006;203(12):2673–82.

230. Okamoto K, Takayanagi H. Osteoimmunology CSH Perspect Med. 2019;9(1):28.
231. Roggia C, Gao YH, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss *in vivo*. *Proc Natl Acad Sci U S A*. 2001;98(24):13960–5.
232. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. T-reg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature*. 2013;500(7461):232–6.
233. Geuking MB, Cahenzli J, Lawson MAE, Ng DCK, Slack E, Hapfelmeier S, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. *Immunity*. 2011;34(5):794–806.
234. Sun S, Luo LJ, Liang WH, Yin Q, Guo J, Rush AM, et al. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. *Proc Natl Acad Sci U S A*. 2020;117(44):27509–15.
235. Zhang HC, Dai Y, Liu Y, Wu T, Li J, Wang XL, et al. Helicobacter pylori colonization protects against chronic experimental colitis by regulating Th17/Treg balance. *Inflamm Bowel Dis*. 2018;24(7):1481–92.
236. Ohlsson C, Nigro G, Boneca IG, Backhed F, Sansonetti P, Sjogren K. Regulation of bone mass by the gut microbiota is dependent on NOD1 and NOD2 signaling. *Cell Immunol*. 2017;317:55–8.
237. Kassem A, Henning P, Kindlund B, Lindholm C, Lerner UH. TLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone loss. *FASEB J*. 2015;29(11):4449–60.
238. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. *Nat Rev Gastroenterol Hepatol*. 2019;16(8):461–78.
239. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013;504(7480):446–50.
240. Asarat M, Apostolopoulos V, Vasiljevic T, Donkor O. Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells *in vitro*. *Immunol Invest*. 2016;45(3):205–22.
241. Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, et al. The shortchain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. *Nat Commun*. 2019;10(1):760.
242. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ, et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts *in vitro*. *J Cell Physiol*. 2011;226(12):3233–41.
243. Rahman MM, Kukita A, Kukita T, Shobuie T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. *Blood*. 2003;101(9):3451–9.
244. Kim DS, Kwon JE, Lee SH, Kim EK, Ryu JG, Jung KA, et al. Attenuation of rheumatoid inflammation by sodium butyrate through reciprocal targeting of HDAC2 in osteoclasts and HDAC8 in T cells. *Front Immunol*. 2018;9:1525.
245. Katono T, Kawato T, Tanabe N, Suzuki N, Iida T, Morozumi A, et al. Sodium butyrate stimulates mineralized nodule formation and osteoprotegerin expression by human osteoblasts. *Arch Oral Biol*. 2008;53(10):903–9.
246. Tyagi AM, Yu MC, Darby TM, Vaccaro C, Li JY, Owens JA, et al. The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10b expression. *Immunity*. 2018;49(6):1116–31.e1117.
247. Lin H, Liu TF, Li X, Gao X, Wu TR, Li P. The role of gut microbiota metabolite trimethylamine N-oxide in functional impairment of bone marrow mesenchymal stem cells in osteoporosis disease. *Ann Transl Med*. 2020;8(16):1009.
248. Vidal C, Li W, Santner-Nanan B, Lim CK, Guillemin GJ, Ball HJ, et al. The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. *Stem Cells*. 2015;33(1):111–21.
249. El Refaey M, Watkins CP, Kennedy EJ, Chang A, Zhong Q, Ding KH, et al. Oxidation of the aromatic amino acids tryptophan and tyrosine disrupts their anabolic effects on bone marrow mesenchymal stem cells. *Mol Cell Endocrinol*. 2015;410(C):87–96.
250. Bliziotis M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, et al. Serotonin transporter and receptor expression in osteocytic MLOY4 cells. *Bone*. 2006;39(6):1313–21.
251. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. *Cell*. 2009;138(5):976–89.
252. Pinedo M, Stanton C. Probiotic bacteria: legislative framework-requirements to evidence basis. *J Nutr*. 2007;137(3 Suppl 2):850S–35.
253. Yuan S, Shen J. Bacteroides vulgatus diminishes colonic microbiota dysbiosis ameliorating lumbar bone loss in ovariectomized mice. *Bone*. 2021;142:115710.
254. Kim DE, Kim JK, Han SK, Jang SE, Han MJ, Kim DH. Lactobacillus plantarum NK3 and bifidobacterium longum NK49 alleviate bacterial vaginosis and osteoporosis in mice by suppressing NF- κ B-linked TNF- α expression. *J Med Food*. 2019;22(10):1022–31.
255. Garcia VG, Knoll LR, Longo M, Novaes VC, Assem NZ, Ervolino E, et al. Effect of the probiotic Saccharomyces cerevisiae on ligature-induced periodontitis in rats. *J Periodontol Res*. 2016;51(1):26–37.
256. Avella MA, Place A, Du SJ, Williams E, Silvi S, Zohar Y, et al. Lactobacillus rhamnosus accelerates zebrafish backbone calcification and gonadal differentiation through effects on the GnRH and IGF systems. *PLoS One*. 2012;7(9):e45572.
257. Yang LC, Lin SW, Li IC, Chen YP, Tzu SY, Chou W, et al. Lactobacillus plantarum GKM3 and lactobacillus paracasei GKS6 supplementation ameliorates bone loss in ovariectomized mice by promoting osteoblast differentiation and inhibiting osteoclast formation. *Nutrients*. 2020;12(7):1914.
258. Jafarnejad S, Djafarian K, Fazeli MR, Yekaninejad MS, Rostamian A, Keshavarz SA. Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, doubleblind, controlled trial. *J Am Coll Nutr*. 2017;36(7):497–506.
259. Narva M, Nevala R, Poussa T, Korpela R. The effect of Lactobacillus helveticus fermented milk on acute changes in calcium metabolism in postmenopausal women. *Eur J Nutr*. 2004;43(2):61–8.
260. Liu JH, Yue T, Luo ZW, Cao J, Yan ZQ, Jin L, et al. Akkermansia muciniphila promotes type H vessel formation and bone fracture healing by reducing gut permeability and inflammation. *Dis Model Mech*. 2020;13(11):dmm043620.
261. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. *Cell*. 2010;142(2):296–308.
262. Maia J, Otake AH, Poças J, Carvalho AS, Beck HC, Magalhães A,

- et al.* Transcriptome reprogramming of CD11b⁺ bone marrow cells by pancreatic cancer extracellular vesicles. *Front Cell Dev Biol.* 2020;8:592518.
263. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, *et al.* Endocrine regulation of energy metabolism by the skeleton. *Cell.* 2007;130(3):456–69.
264. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell.* 2006;126(4):789–99.
265. Waung JA, Bassett JHD, Williams GR. Thyroid hormone metabolism in skeletal development and adult bone maintenance. *Trends Endocrinol Metab.* 2012;23(4):155–62.
266. Monfoulet LE, Rabier B, Dacquin R, Anginot A, Photsavang J, Jurdic P, *et al.* Thyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone mass. *J Bone Miner Res.* 2011;26(9):2036–44.
267. Daya NR, Fretz A, Martin SS, Lutsey PL, Echouffo-Tcheugui JB, Selvin E, *et al.* Association between subclinical thyroid dysfunction and fracture risk. *JAMA Netw Open.* 2022;5(11):e2240823.
268. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. *Thyroid.* 2002;12(5):411–9.
269. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. *Calcified Tissue Int.* 2005;77(3):139–44.
270. Yuan G, Li Z, Lin X, Li N, Xu R. New perspective of skeletal stem cells. *Biomater Transl.* 2022;3(4):280–94.
271. Guo J, Wang F, Hu Y, Luo Y, Wei Y, Xu K, *et al.* Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases. *Cell Rep Med.* 2023;4(1):100881.
272. Liu H, Zhang H, Wang S, Cui J, Weng W, Liu X, *et al.* Bone-targeted bioengineered bacterial extracellular vesicles delivering siRNA to ameliorate osteoporosis. *Compos Part B-Eng.* 2023;255:110610.
273. Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. *Biomater Transl.* 2022;3(3):175–87.
274. Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. *Nat Rev Drug Discovery.* 2022;21(5):379–99.
275. Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organ-on-chips: into the next decade. *Nat Rev Drug Discovery.* 2021;20(5):345–61.
276. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. *Nat Rev Genet.* 2022;23(8):467–91.
277. Hu Y, Zhang H, Wang S, Cao L, Zhou F, Jing Y, *et al.* Bone/cartilage organoid on-chip: construction strategy and application. *Bioact Mater.* 2023;25:29–41.
278. Chou DB, Frisimantas V, Milton Y, David R, Pop-Damkov P, Ferguson D, *et al.* On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. *Nat Biomed Eng.* 2020;4(4):394–406.
279. McAleer CW, Long CJ, Elbrecht D, Sasserath T, Bridges LR, Rumsey JW, *et al.* Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. *Sci Transl Med.* 2019;11(497):eaav1386.
280. Herland A, Maoz BM, Das D, Somayaji MR, Prantil-Baun R, Novak R, *et al.* Quantitative prediction of human pharmacokinetic responses to drugs *via* fluidically coupled vascularized organ chips. *Nat Biomed Eng.* 2020;4(4):421–36.
281. Kim E, Choi S, Kang B, Kong J, Kim Y, Yoon WH, *et al.* Creation of bladder assembloids mimicking tissue regeneration and cancer. *Nature.* 2020;588(7839):664–9.
282. Paşca SP, Arlotta P, Bateup HS, Camp JG, Cappello S, Gage FH, *et al.* A nomenclature consensus for nervous system organoids and assembloids. *Nature.* 2022;609(7929):907–10.

<https://doi.org/10.1186/s40779-024-00540-9>

Cite this article as: Deng AF, Wang FX, Wang SC, Zhang YZ, Bai L, Su JC. Bone-organ axes: bidirectional crosstalk. *Mil Med Res.* 2024;11(1):37.